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The Role of RalA and RalB in Cancer 
 
Samuel C. Falsetti  
ABSTRACT 
Ras genes are frequently mutated in human cancers and present compelling 
targets for therapeutic intervention. While previous attempts to directly inhibit oncogenic 
Ras function have largely been unsuccessful use of targeted agents to inhibit the three 
primary oncogenic pathways activated by mutated Ras: RalGEF-Ral, PI3K-Akt and Raf-
MEK-Erk, is an area of intense investigation. Here, we describe the ability of a novel 
pharmacological inhibitor of geranylgeranyltransferase I, GGTI-2417, to inhibit Ral 
prenylation and localization. We further used a Ral rescue system to selectively preserve 
RalA and RalB function and localization during GGTI-2417 treatment and determine the 
precise roles for inhibition of Ral prenylation in the GGTI anti-cancer response. 
Specifically, we determined inhibition of RalA is required for GGTI-attenuation of 
anchorage independent growth whereas inhibition of RalB is required for inhibition of 
proliferation, induction of apoptosis, suppression of survivin and induction of p27Kip1. We 
next determined the role of RalGEF-Ral signaling as well as PI3K-Akt and Raf-MEK-
Erk signal transduction pathways in an in vitro model of human ovarian surface epithelial 
(T80 HOSE) cell Ras-dependent transformation. Using both small interfering RNA 
(siRNA) and pharmacological inhibitors of Ral, PI3K and MEK we determined that Ras 
signaling via Ral and PI3K but not MEK is required for ovarian oncogenesis. 
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Furthermore, stable expression of Ras mutants unable to activate Raf-MEK-Erk signaling 
were able to robustly transform T80 cells. Since we had confirmed the importance of Ral 
proteins to human epithelial malignancies we next sought to explore the molecular 
interactions governing Ral transformation using a proteomics approach to rapidly identify 
proposed Ral interacting partners. Using immunoprecipition of transiently overexpressed 
FLAG-tagged RalA and RalB followed by 1D-gel separation and tandem MS/MS 
analysis we determined a database of proposed Ral interacting proteins. One of these, 
RACK1, is a validated RalA and RalB interacting protein which is at least partially 
required for Ras and Ral transformation. These results provide both a strong impetus and 
a solid basis for future studies into the mechanisms of RalA- and RalB- dependent 
transformation. 
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The Ras Superfamily 
 
In order to understand the role of Ral in cancer it is necessary to understand the 
role of Ras genes in oncogenesis. Members of the Ras and Rho branches of the Ras 
superfamily of small GTPases are critically involved in the regulation of many biological 
events critical to the regulation of cellular homeostasis such as cell cycle control, cell 
survival, death, differentiation, development and growth (11, 93). The aberrant activation 
or inactivation of Ras family proteins is believed to be important in the induction of 
oncogenesis. In addition to the three Ras proteins (H-, N- and K-Ras), other Ras family 
proteins with validated roles in oncogenesis include R-Ras, Ral, Rheb, Di-Ras and 
Noey2/ARHI small GTPases.  Rho family GTPases (e.g., RhoB, RhoC, Rac1b, DBC2) 
are also implicated in oncogenesis (73). There are 156 known genes in the Ras 
superfamily and at least 166 known Ras superfamily isoforms (see Table 1 on following 
page).  
6
22Ral
109Other 
11Ran 
3027Sar1/ Arf
6361Rab
2220Rho
3936Ras  
Known isoforms Human genes Family
Total                                              156          166       
Adapted from Wennerberg K, Rossman KL, Der CJ. Journal 
of Cellular Science.2005; 118(5); 843-846.
Table 1: The Ras Superfamily
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Members of the Ras superfamily are also referred to as molecular switches which 
cycle from the “on” (GTP-bound) to “off” position (GDP-bound) through an intrinsic 
GTPase activity (Figure 1, following page). Two classes of proteins regulate the catalytic 
rate of Ras superfamily GTPase activity: GTPase activating proteins (GAPs) and 
guanine-nucleotide exchange factors (GEFs). GAP proteins activate the intrinsic GTPase 
activity of Ras family members causing Ras to remain in a preferentially GDP-bound 
state whereas GEFs catalyze the exchange GDP for GTP causing Ras to be in a 
preferentially GTP-bound state (2, 16, 18, 46, 102). Mutational activation of Ras proteins 
typically involves point mutation of key residues, for example amino acids 12 and 61 of 
Ras (see Figure 2, following page), essential for GAP binding; this gradually reduces the 
GTPase activity of Ras and keeps it in a persistently activated, GTP-bound state (17, 63, 
79, 87, 95, 96). The nucleotide bound state dictates the orientation of the effector loop 
regions of Ras family proteins; when GTP is bound the effector loop regions become 
accessible to the Ras-binding regions of cognate effector proteins activating multiple 
downstream effector pathways (60). 
8
GEFs
“ON” Ras GDP
RasGAP
Sos1/2Grb2
RTKs
Ras GTP “OFF”
Figure 1: The Ras GTP-GDP Cycle
Abbreviations: RTKs (receptor tyrosine kinases), SOS (son of sevenless), Ras-GTP 
(GTP-bound Ras), Ras-GDP (GDP-bound Ras), GEFs (guanine nucleotide exchange 
factors), RasGAP (Ras GTPase activating protein) 
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Adapted from Pai EF, Krnngel U, Petsko GA, et al .EMBO Journal. 
1990; 9(8); 2351-9. 
Figure 2: Ras GTPase Domains and Point Mutations 
H-Ras 
Switch I Switch II  
* *
* Amino acid  12
* Amino Acid 61
CAAX
10
Ras proteins engage over twenty known effectors, which in turn activate a variety 
of other proteins. Three of the Ras effector pathways, phosphotidyl inositol tri-phosphate 
kinase (PI3K)/Akt, Raf/MEK/Erk and Ral guanine nucleotide dissociation stimulator 
(RalGDS)/Ral) (7, 21, 35, 81) are at least partially required for constitutively activated 
Ras to initiate oncogenesis in certain cell types (26, 31, 41, 45, 64, 65, 71) [Figure 3, see 
following page]. Ras proteins, as the archetypical oncogenic small GTPases, are the most 
intensively studied members of the Ras superfamily. However, the vast majority of 
known small GTPases, despite being similar to Ras, are far less extensively studied and 
play undefined roles in oncogenesis. Furthermore, these gene products have, at least 
potentially, as many or more effectors as Ras. Some of these proteins, such as members 
of the Rac and Ral subfamilies, are known to interact directly with effectors which are 
distinct from those of Ras. Taken as a whole these observations suggest that the true 
range of cellular pathways governed by small GTPases remain to be determined.  
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Ras-GTP
Ral-
GEF
RalA-
GTP
RAF
MEK
Erk1/2
PI3K
Akt
RalB-
GTP
TRANSFORMATION
Cell cycle progression
Survival, AIG, Motility
Invasion, Transcription 
Tiam1
NORE1Rin1
AF6
PLC-E
Figure 3: Ras Signaling and Transformation
Abbreviations: Ras-GTP (GTP-bound Ras), Ral-GEF (Ral guanine nucleotide 
exchange factor), RalA/B-GTP (GTP-bound Ral), PLC-E (phospholipase C 
epsilon), AIG (anchorage independent growth)
12
The Role of Prenylation in Ras Superfamily Function 
 
The oncogenic functions of the Ras and Rho proteins require posttranslational 
processing by prenyltransferase enzymes (37, 39, 101). The two enzymes responsible for 
prenylation of Ras family proteins are farnesyltransferase (FTase) and 
geranylgeranyltransferase I (GGTase I) (6, 8, 9, 55, 74, 75, 100, 101), which covalently 
attach the 15-carbon farnesyl and 20-carbon geranylgeranyl lipids, respectively, to the 
cysteine  of proteins with the carboxy terminal tetrapeptide consensus sequence CAAX,  
(C is cysteine, A is any aliphatic amino acid and X is any carboxyl-terminal amino acid), 
see figure 2. In general, FTase farnesylates proteins in which X is methionine or serine 
(70), whereas GGTase I geranylgeranylates proteins in which X is leucine or isoleucine 
(24). Ras proteins that are mutationally rendered unprenylatable lose their oncogenic 
activity and fail to properly localize within the cell (37, 39).   Similarly, prenylation of 
other proteins in the Ras and Rho families is essential to their activities (1, 37, 49) . 
  The fact that prenylation is required for the oncogenic activity of small GTPases 
prompted us and others to design FTase and GGTase I inhibitors (FTIs and GGTIs) as 
potential anticancer drugs (28, 50, 68, 105).  While numerous studies have shown that 
FTIs suppress oncogenic and tumor survival pathways, the actual mechanism by which 
FTIs inhibit tumor growth is not known (67, 76).  Thus, while designed originally as anti-
Ras inhibitors, the Ras isoforms most commonly mutated in human cancers (N- and K-
Ras) escape FTI inhibition by undergoing alternative prenylation by GGTase I (72, 85, 
94).  Therefore, the critical farnesylated proteins that FTIs target to induce these effects 
are not known (67, 76).  Similarly, the GGTase I substrates important for the anti-tumor 
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activity of GGTIs are not clearly understood yet.  While Rac1 and Rac3 Rho family 
proteins have been implicated as candidate targets for GGTIs (38), other important 
targets remain to be identified.   Previous studies have demonstrated that GGTIs, at least 
partially require, the inhibition of  Akt serine/threonine kinase and expression of survivin 
(15, 83), however it remains unknown how inhibition of geranylgeranylated proteins 
results in downregulation of these critical targets.  Furthermore, GGTIs also induce 
p21waf, inhibit CDK activity, phosphorylation of Rb and lead to G0/G1 cell cycle 
accumulation (61, 68, 83-85, 90).  In animal models, GGTIs both inhibit tumor growth in 
nude mouse xenografts and induce tumor regression in transgenic mice (82, 83). The 
GGTase I substrates targeted by GGTIs to induce their anti-neoplastic effects are not 
known.  Logical candidates include other Ras and Rho family proteins with roles in 
oncogenesis, such as the Ras-like RalA and RalB small GTPases.  
The increasing evidence for Ral GTPases in oncogenesis prompted our interest in 
evaluating Ral GTPases as important targets for GGTI anti-tumor activity.  Both RalA 
and RalB C-termini contain a CAAX sequence that predicts prenylation and RalA has 
been shown to be geranylgeranylated (43).  Furthermore, RalA and RalB are involved in 
many oncogenic steps that are inhibited by GGTIs.  Therefore, in chapter two of this 
thesis we investigated whether some of the anti-neoplastic effects of GGTIs are mediated 
by inhibition of the geranylgeranylation and function of RalA and/or RalB.   
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Tissue- and Species- Specific Mechanisms of Ras Transformation 
 
 
Understanding the mechanisms of Ras transformation has become a critical 
component of developing a new generation of targeted therapeutics. Over 30% of human 
cancers have mutationally activated Ras (32).  As we review in this section, over twenty 
years of research, using a variety of in vitro model systems, has defined a series of 
species and tissue-specific mechanisms of Ras-transformation. These in vitro cell systems 
fall into two general categories: spontaneously immortalized- and genetically defined- 
model systems; both of these are minimally transformed systems which provide a 
platform to assess the effects of stable expression of oncogenic Ras (30, 32).  
Furthermore, these systems provide an easily evaluable means of determining the 
mechanism by which Ras drives species- and tissue- specific transformation. In this 
section we first review the mechanisms of Ras-transformation in spontaneously 
immortalized cell systems followed by the more recently used genetically defined models 
of human cancer.  
15
Use of Spontaneously Immortalized Cell Systems to Study Ras Transformation 
 
 
Three of the Ras signaling pathways, RalGEF/Ral, PI3K/AKT and Raf/Mek/Erk 
have been primarily implicated in the ability of oncogenic Ras to initiate and maintain the 
transformed phenotype (41, 45, 51, 75, 78). The Raf/Mek/Erk pathway has been widely 
assumed to be the primary pathway of Ras transformation in all cell types. This 
inaccurate assessment is mostly derived from initial reports which, correctly, determined 
that the transformative capabilities of Ras oncogenes relied upon activity of the 
Raf/Mek/Erk pathway in spontaneously immortalized mouse fibroblast NIH-3T3 cells 
(41, 45). However, a variety of other spontaneously immortalized cell systems have been 
used to describe an array of species- and tissue- specific requirements for Ras 
transformation.  
Spontaneously immortalized rat intestinal epithelial (RIE) cells have been used as 
a model system to assess the involvement of the Raf, Akt and Ral signaling pathways in 
Ras mediated transformation. Specifically, Sheng and colleagues (77) found that 
pharmacologic blockade of PI3K/Akt inhibited Ras mediated transformation however,  
myristolated-Akt was not sufficient for transformation but was transforming when co-
expressed with a constitutively activated C-Raf mutant (Delta-Raf-22W). Further work 
by Der and colleagues (64) compared transformation of NIH-3T3 side by side with RIE 
cells. While both Ras and a constitutively activated C-Raf (Raf-CAAX) could transform 
NIH-3T3 only Ras could independently transform RIE cells. Gangarosa and colleagues 
(27) compared the ability of K-Ras12V, H-Ras12V and Raf-CAAX to transform RIE (and 
the similar intestinal epithelial cell line-6, IEC-6 cells) by measuring the ability of the 
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oncogenes to elicit an external epidermal growth factor receptor (EGFR) autocrine loop. 
In these cells oncogenic Ras, but not Raf, could elicit this autocrine loop and transform 
RIE and IEC6 cells. Further work by this group in collaboration with Der and colleagues 
(65) demonstrated that while Ras transformation in RIE cells could be blocked by the 
MEK inhibitor PD98059, Ras mutants defective for Raf activation could still transform 
RIE cells, albeit at a reduced potency. These results argue that while both Raf and PI3K 
signaling are partially required for Ras transformation of rat intestinal epithelial cells 
neither is sufficient to independently initiate oncogenesis.  
Immortalized human mammary epithelial cells (MCF-10A) derived from 
dysplastic mammary tissue were used as a model system to assess the involvement of 
various Ras downstream signaling molecules in Ras mediated transformation. Der and 
colleagues (64) compared transformation of NIH-3T3 side-by-side with MCF-10A cells. 
Both oncogenic Ras and Raf-CAAX could transform NIH-3T3 but only oncogenic Ras 
was sufficient to transform MCF-10A cells. The Salomon group (57) further determined 
that oncogenic Ras induced an EGFR-autocrine loop in MCF-10A cells and determined 
that both EGFR activation and MEK activity were required for full transformation. These 
results argue for a more complex mechanism of transformation in MCF-10A cells than in 
NIH-3T3 cells.  
Spontaneously immortalized rat ovarian surface epithelial (ROSE) cells have been 
used to determine the requirements for Ras mediated transformation. In these cells the 
Der group (88) determined that stable expression of H-Ras12V activated Raf/MEK/ERK 
signaling but did not activate PI3K signaling. Here, constitutively active Raf could 
partially reconstitute both Ras-transformation and associated morphology changes. The 
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Erickson group further defined this system (12) and determined that all three effector 
pathways (Raf, PI3K, and RalGDS) were required for full transformation and the 
production of cathepsin L. 
18
Use of Genetically Defined Cell Systems to Study Ras Transformation 
 
 
While spontaneously immortalized cell systems have proven to be useful models 
for the study of transformation requirements it is important to note that spontaneous 
immortalization proceeds through poorly defined processes. Conversely, genetically 
tractable models of human epithelial immortalization, while experimentally defined, offer 
an alternative means of investigating mechanisms of specific oncogene induced 
transformation in cells with a defined genetic background which closely mimics the 
genetic abnormalities present in the early and late stages of human carcinogenesis (51).  
Human embryonic kidney cells sequentially immortalized by the catalytic subunit 
of human telomerase (hTERT) and the SV40-large T and –small t antigens (which 
inactivate the key tumor suppressors p53, Rb and protein phosphotase-2A), or HEK-HT 
cells, are derived from the embryonic mesoderm. HEKs are a mixed lineage cell line 
known to express both epithelial and mesenchymal markers that become fully 
transformed by stable expression of oncogenic Ras (30). The Counter group determined 
that H-Ras12V37G was, by itself, sufficient for transformation in this cell line (31). This 
concept was further supported by the demonstration that constitutively activated Rlf or 
activated RalA, but not the related RalB, was capable of transforming these cells (51). In 
contrast to these results the Weinberg group further defined the requirements for Ras-
mediated transformation of this system (69). Rangarajaran and colleagues found that only 
paired expression of H-Ras12V37G (only activating RalGDS) and H-Ras12V40C (only 
activating PI3K), but not H-Ras12V35S (only activating Raf) and H-Ras12V40C nor H-
Ras12V37G and H-Ras12V35S, could fully transform HEK-HT cells. This concept was further 
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supported by evidence that stable expression of constitutively activated Akt and Rlf (a 
Ral-GEF) could induce transformation in soft agar.  
In contrast, human mammary epithelial cells (HMECs) immortalized by hTERT 
and SV-40-large T antigen, HMECs, become fully transformed by stable expression of 
oncogenic Ras (19) but differ in the Ras-downstream signaling requirements from HEK-
HTs. The Weinberg group has investigated the requirements for Ras-mediated 
transformation of this system (69) and determined that only co-activation of all three 
primary Ras effectors (Raf, RalGDS, and PI3K) can transform HMEC cells.  
A variety of other human-derived genetically defined models of transformation 
have been used to address mechanisms of Ras transformation. Human fibroblasts 
immortalized by hTERT and SV4040-large T antigen, BJ fibroblasts, become fully 
transformed by stable expression of oncogenic Ras (30). The Weinberg group further 
defined the requirements for Ras-mediated transformation of this system (69). 
Rangarajaran and colleagues found that only paired expression of H-Ras12V35S (only 
activating Raf-1) and H-Ras12V37G (only activating RalGDS), but not H-Ras12V35S and H-
Ras12V40C not H-Ras12V37G and H-Ras12V40C, could fully transform BJ fibroblasts. Human 
esophageal epithelial cells immortalized by hTERT and SV40, EPC2 cells, can be fully 
transformed by either H-Ras12V, c-Myc or activated AKT (42).  
A variety of other tissue types following the same sequence of genetic events 
(hTERT activation, inactivation of p53 and Rb, and transduction of oncogenic Ras), but 
using non-viral approaches, have been used to create other genetically defined models of 
human cancer. Counter and colleagues (40) report the creation of an alternative human 
mammary epithelial cell system, the first human myoblast cell system, and an alternative 
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human embryonic kidney cell system.  Linardic and colleagues report the creation of 
rhabdomyosarcoma model systems from human skeletal muscle cell precursors and 
committed human skeletal muscle myoblasts (53). Also, human bronchial epithelial cells 
immortalized by hTERT, CDK4 and siRNA to p53, HBECs, can be partially transformed 
by stable transduction of K-Ras12V or mutant EGFR (E746-A750 del or LL859R). The 
Minna group determined that either Ras or EGFR could induce transformation and 
invasion in a 3-dimensional organotypic culture (103).  
Additionally, while not genetically defined nor able to be fully transformed 
human thyroid epithelial primary cells can be induced to a hyper-proliferative state by 
expression of oncogenic Ras which closely resembles the phenotype of an early stage 
thyroid tumor, follicular adenoma. The Wynford-Thomas group (4) used these cells to 
investigate the contributions of the Ras-effectors Raf, PI3K and RalGDS to induction of 
thyrocyte hyperproliferation. Co-expression of the three Ras effector mutants which only 
bind RalGDS, Raf, and PI3K could fully recapitulate the hyperproliferative state induced 
by fully oncogenic Ras while combinations of any of these two mutants was not 
sufficient.  
Importantly for our studies, human ovarian surface epithelial cells immortalized 
by stable expression of hTERT and SV40-large T antigen, T80 cells, have been recently 
established as models for human ovarian oncogenesis. These cells were created by the 
Bast group (54) and are fully transformed following stable expression of either H-Ras12V 
or K-Ras12V. A similar model system, created by Kusukari and colleagues (48), could 
also be transformed by stable expression of either H-Ras12V or c-erbB-2.  
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Use of an In Vitro Model of Human Ovarian Cancer to Study the Mechanism of Ras 
Transformation: Implications for RalA and RalB 
 
 Ovarian cancer is the primary cause of death among gynecological malignancies 
and is the 5th leading cause of cancer deaths among women in the United States (29). 
Despite the high incidence of ovarian cancer among women and the relative lethality of 
the disease little is known about the precise mechanism of transformation of human 
ovarian surface epithelial (HOSE) cells. Indeed, multiple mechanisms of ovarian surface 
epithelial cell transformation have been proposed and are believed to be sub-type specific 
(3). The two most common sub-types of ovarian cancer, high-grade serous and mucinous 
ovarian carcinoma (29), are commonly diagnosed at late-stage and are frequently lethal 
due to a high-propensity for both metastasis and drug-resistant recurrence (3, 29). It is 
thus of critical importance to define the mechanism of ovarian epithelial cell 
transformation both for a more precise understanding of the underlying genetic risk 
factors as well as for the development of targeted therapies .  
 Epithelial neoplasias, such as ovarian cancers, exhibit multiple genetic aberrations 
in key tumor suppressor genes, so-called “cellular gatekeepers” such as p53 and Rb (32). 
Indeed, over 50% of ovarian cancers exhibit missense mutations in P53 (47, 56). 
Furthermore, over 80% of human ovarian cancers examined have been shown to have 
mutational defects in one or more of the genes involved in the Rb tumor suppressive 
pathway, such as CDK4, cyclin D1, and Rb (33). Activation of human telomerase activity 
is another well-recognized defect of human epithelial neoplasms (32) with ovarian cancer 
being no exception to this rule (13). In addition to p53, Rb and hTERT genetic 
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abnormalities activation of one or more proto-oncogenes is a pivotal fourth event in the 
development of malignant disease.  
One of the most well studied mechanisms of oncogenesis in human cancer is 
mutational activation of members of the Ras gene family. Mutations in Ras gene family 
members (H-, K-, and N- Ras) are known to occur in approximately 30% of human 
cancers (78). Numerous studies have demonstrated that mutational activation of K-Ras, 
through missense mutations at codons 12 and 13, occurs with high frequency (27-69%) in 
certain subtypes of ovarian cancers (14, 25, 36, 62, 89). Similar mutations in the H-Ras 
proto-oncogene have been determined to occur in ovarian cancer subtypes though there is 
considerable disagreement over the frequency (20, 89, 104). For example, while one 
study has found that H-Ras activations occur with variable frequency depending on 
subtype (33% of borderline ovarian tumors, 13% of mucinous adenocarcinomas, and 7% 
of serous adenocarcinomas and in 6% of primary invasive ovarian carcinomas) (89) 
others have found H-Ras mutations occur infrequently (0-12.5%) (20, 104) . 
A role for Ras mutation in ovarian cancer progression is especially well 
recognized in mucinous sub-type ovarian tumors where the incidence of K-Ras proto-
oncogene mutation increases profoundly during the progression of disease (62). For 
example, Mok and colleagues found a high, progression-dependent incidence of K-Ras 
activation at codons 12 and 13 in 13% of mucinous adenomas, 33% of mucinous tumors 
at the borderline, and 46% of mucinous carcinomas (62). Similar results, in which K-Ras 
mutation incidence increases dramatically throughout disease progression, have been 
reported by many other groups (14, 20, 36, 62, 89). These studies have primarily 
examined mutations at codons 12 and 13 however, activating Ras mutations are also 
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known to occur in some cancers at codon 61; thus it is possible that the actual incidence 
of Ras mutations in mucinous ovarian cancer has been underestimated.   
K-Ras mutation have also been detected, albeit to a lesser degree (0-12%), in 
high-grade serous sub-type ovarian cancer, the most common form of ovarian 
malignancy (62). It is interesting to note that a much higher incidence of Ras mutation 
exists in low-grade serous malignancy. Indeed, over 68% of low grade serous tumors 
have either a K-Ras or B-Raf mutation (59). Furthermore, these mutations occur in a 
mutually exclusive (59) manner suggesting that the primary mechanism of K-Ras 
mutation in low-grade serous is through B-Raf activation. Additionally, the presence of 
K-Ras proto-oncogene mutations in up to 48% of borderline ovarian epithelial tumors 
(62) indicates a role for K-Ras mutation in the early events of low-grade serous ovarian 
neoplasia. Given the lack of B-Raf mutations in high-grade serous carcinoma the precise 
mechanism of Ras mediated transformation in this tumor sub-type remains a mystery, as 
does the etiology of disease progression. While genetic analysis of patient tumors of 
multiple ovarian subtypes suggest Ras mutation is a frequent occurrence analysis of 
downstream Ras effectors, such as Raf, has not yielded a consensus view of the 
mechanism for Ras transformation. However, other methods are available for 
determining the necessary components of ovarian cell-type specific Ras transformation.  
Recently, Der and colleagues described the mechanism of Ras transformation in 
spontaneously immortalized rat ovarian surface epithelial (ROSE) cells (88).  They 
assessed the transformative ability of retrovirally transduced H-Ras and constitutively 
active mutants of the Ras downstream effectors Raf, Ral- GDS and the catalytic subunit 
of PI3K (p110) to determine, for the first time, which Ras effectors are capable of 
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independent ovarian cell transformation. In this system Raf, but not p110 or Ral-GDS, 
was capable of independently transforming in a manner similar to H-Ras12V. 
Interestingly, H-Ras12V was unable to activate PI3K catalytic activity or stimulate 
activation of Akt in this cell line. These results suggest that Ras effector utilization varies 
in a tissue specific manner. While this system has been useful in suggesting which 
signaling cascades are required for Ras transformation in ovarian epithelial cells, the 
ROSE system is neither genetically defined nor of human origin and thus, while 
suggestive of a role for Raf in ovarian transformation, has unknown prognostic 
significance for human ovarian oncogenesis.  
 Since that seminal discovery by Der and colleagues a genetically defined human 
model of ovarian malignancy has been developed which recapitulates the critical events 
in neoplasia (54). The T80 cell line is derived from primary human ovarian surface 
epithelial cells engineered to express SV40T and hTERT. Upon the addition of 
retrovirally transduced H-Ras12V these cells, referred to as T80H, acquire anchorage 
independent growth capability in soft agar, a reliable estimate of transformation, and are 
capable of forming xenograft tumors in a SCID mouse model. This transformation 
requires continued expression of H-Ras (98) and, as such, is a bona fide model of Ras-
dependent, ovarian cell-type-specific transformation. In chapter 3 of this thesis we have 
used these cells as well as our own stable K-Ras12V expressing variant (T80K) to 
investigate the required downstream signaling components of Ras transformation in 
human ovarian surface epithelial cells. 
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Ral Proteins are Central Mediators of Oncogenesis 
 
 In further confirmation of a role for the Ral small GTPases in oncogenesis both 
RalA and RalB, which are over 85% similar, have been identified as critical divergent 
mediators of multiple tumorigenic processes, including metastasis, invasion, anchorage 
independent growth, survival and cell motility (10, 22, 66, 91, 92, 97).  Specifically, 
depletion of RalA by siRNA has been shown to inhibit anchorage independent 
proliferation of multiple human cancer cell lines, such as the HeLa cervical and SW680 
prostate cancer cell lines  (10) as well as multiple human pancreatic cancer cell lines (52). 
Also, RalA expression is required for anchorage independent growth of sequentially Ras 
transformed human ovarian (see Chapter 3) and kidney cells (51). Similarly, stable 
depletion of RalA, but not RalB, by shRNA has been shown to inhibit tumor formation 
and metastasis of multiple human pancreatic cancer cell lines in athymic nude mice (52). 
Further confirming a role for RalA in metastasis, stable overexpression of constitutively 
activated RalA has been shown to promote both standard and experimental metastasis in 
vivo (86, 91) and in human prostate cancer cells, stable expression of activated RalA 
promotes bone, but not brain, metastasis (99). Even in non-epithelial cancers there is 
emerging evidence that RalA is involved in tumorigenicity; for example, in human 
HT1080 fibrosarcoma cells stable overexpression of activated RalA promotes anchorage 
independent growth (97). In agreement with these findings two cellular processes thought 
to promote metastasis and anchorage independent growth: cell motility and invasion, are 
inhibited by siRNA-mediated depletion of RalA in multiple human renal cancer cell lines 
(66).   
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 While RalA has been well validated to play an essential role in anchorage 
independent processes in multiple tissue types the role of RalB has been determined to be 
far more tissue specific. For example, while depletion of either RalA or RalB inhibits 
anchorage independent growth in human ovarian epithelial cells transformed by either H- 
or K-Ras12V (Chapter 3), only depletion of RalA, but not RalB, inhibits H-Ras12V 
transformation of HEK-HT cells (51). We, as well as others have previously determined a 
role for RalB, but not RalA in the survival of multiple human cancer cell lines (10, 22). 
Specifically, White’s group has found that depletion of RalB by siRNA induces apoptosis 
in both HeLa and SW680 human cancer cell lines (10). Similarly, our results in chapter 
two have established, using a chemical biology approach, that inhibition of a RalB, but 
not RalA, survival pathway underlies the apoptotic response to geranylgeranyltransferase 
I inhibitors (GGTIs) (22). Specifically, Ral proteins have been shown to require 
geranylgeranylation for localization and interaction with other proteins (34, 44, 58, 80). 
Importantly, stable expression of GGTI-resistant RalB in the human pancreatic 
carcinoma cell line MiaPaCa2 renders cells resistant to GGTI-induced apoptosis (22). 
Taken as a whole, these studies strongly suggest a role for RalB tumor survival in a wide 
array of tissue types as well as a tissue specific role in anchorage independent growth.  
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Ral Effectors and Control of Cellular Processes 
 
  
Despite the wealth of information regarding the role of Ral small GTPases in 
transformation very little is known about the pathways through which Ral exerts these 
effects. For example, while RalA and RalB bear a high homology to Ras and over 20 
effectors are known for the Ras isoforms (5, 78),only 6 Ral effectors have been 
described: phospholipase D1 (PLD1), the exocyst components Sec5/ Exo84, Filamin A, 
ZO-1 N-terminally associated binding protein (ZONAB) and Ral binding protein-1 
(RalBP1/RLIP) (23). Precise roles for these proteins in the various transformation 
specific processes that are regulated by RalA and RalB remain poorly defined. Despite 
the fact that RalA and RalB are commonly thought of as Ras effector proteins, both RalA 
and RalB are found in the hyperactivated state independently of Ras in human pancreatic 
tumors (51, 52). Thus, novel means of Ral activation and inactivation may constitute an 
important and undescribed mechanism of transformation. However, no Ral GTPase 
activating proteins (RalGAPs), which would negatively regulate RalA and RalB, have 
been described to date. Also, RalA and RalB are known to regulate diverse physiological 
processes such as signaling via STAT3, NF-KB, JNK and AFX (23). However, the 
intermediate proteins in these signal transduction pathways through which RalA and 
RalB exert these functions remain unknown.  
 In an effort to more fully understand the protein interactions that govern the 
biological activities of RalA and RalB we have used proteomic analysis, in chapter 4 of 
this thesis, to describe a proposed database of Ral interacting proteins for the first time. 
We have uncovered a wealth of potential RalA and RalB interacting partners and used a 
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systems biology approach to analyze the broad themes that emerge from this proposed 
database. We have further demonstrated that one of these proteins, receptor for activated 
C-kinase (also known as GBLP1 or RACK1), is a potential RalA and RalB interacting 
protein that is required for both Ras and Ral mediated transformation of human ovarian 
surface epithelial (T80) cells. In addition to uncovering a critical role for RACK1 
expression in both Ras- and Ral- mediated transformation our proteomics study is the 
first large-scale analysis of the Ral “interactome”. This database will provide the 
emerging field of Ral study with a wealth of potential RalA and RalB biological effectors 
and potential regulators of Ral cellular activities.  
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Figure 4: Ral Signaling
Abbreviations: Ral-GTP (GTP-bound Ral), PLD1 (phospholipase D1), 
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 Abstract 
Geranylgeranyltransferase I inhibitors (GGTIs) are presently undergoing advanced 
preclinical studies and have been shown to disrupt oncogenic and tumor survival 
pathways, to inhibit anchorage-dependent and –independent growth and to induce 
apoptosis.  However, the geranylgeranylated proteins that are targeted by GGTIs to 
induce these effects are not known.  Here we provide evidence that the Ras-like small 
GTPases RalA and RalB are exclusively geranylgeranylated and that inhibition of their 
geranylgeranylation mediates, at least in part, the effects of GGTIs on anchorage-
dependent and –independent growth and tumor apoptosis. To this end, we have created 
the corresponding carboxyl terminal mutants that are exclusively farnesylated, verified 
that they retain the subcellular localization and signaling activities of the wild type 
geranylgeranylated proteins and that Ral GTPases do not undergo alternative prenylation 
in response to GGTI treatment. By expressing farnesylated,  GGTI-resistant RalA and 
RalB in Cos7 cells and the human pancreatic MiaPaCa2 cancer cells followed by GGTI-
2417 treatment we demonstrated that farnesylated RalB, but not RalA, confers resistance 
to the pro-apoptotic and anti-anchorage-dependent growth effects of GGTI-2417.  
Conversely, farnesylated RalA but not RalB expression renders MiaPaCa2 cells less 
sensitive to inhibition of anchorage-independent growth. Furthermore, farnesylated RalB, 
but not RalA , inhibits the ability of GGTI-2417 to suppress survivin and induce p27Kip1 
protein levels. We conclude that RalA and RalB are important, functionally distinct 
targets for GGTI-mediated tumor apoptosis and growth inhibition.   
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 Introduction 
Members of the Ras and Rho branches of the Ras superfamily of small GTPases 
are critically involved in the regulation of many biological events critical to the 
regulation of cellular homeostasis such as cell cycle control, cell survival, death, 
differentiation, development and growth (9, 53). The aberrant activation or inactivation of 
Ras family proteins is believed to be important in the induction of oncogenesis. In 
addition to the three Ras proteins (H-, N- and K-Ras), other Ras family proteins with 
validated roles in oncogenesis include R-Ras, Ral, Rheb, Di-Ras and Noey2/ARHI small 
GTPases.  Rho family GTPases (e.g., RhoB, RhoC, Rac1b, DBC2) are also implicated in 
oncogenesis (41).     
The oncogenic functions of the Ras and Rho proteins require posttranslational 
processing by prenyltransferase enzymes (20, 23, 56). The two enzymes responsible for 
prenylation of Ras family proteins are farnesyltransferase (FTase) and 
geranylgeranyltransferase I (GGTase I) (3-5, 29, 42, 43, 55, 56), which covalently attach 
the 15-carbon farnesyl and 20-carbon geranylgeranyl lipids, respectively, to the cysteine  
of proteins with the carboxy terminal tetrapeptide consensus sequence CAAX,  (C is 
cysteine, A is any aliphatic amino acid and X is any carboxyl-terminal amino acid). In 
general, FTase farnesylates proteins in which X is methionine or serine (37), whereas 
GGTase I geranylgeranylates proteins in which X is leucine or isoleucine (12). Ras 
proteins that are mutationally rendered unprenylatable lose their oncogenic activity and 
fail to properly localize within the cell (20, 23).   Similarly, prenylation of other proteins 
in the Ras and Rho families is essential to their activities (1, 20, 25) . 
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   The fact that prenylation is required for the oncogenic activity of small GTPases 
prompted us and others to design FTase and GGTase I inhibitors (FTIs and GGTIs) as 
potential anticancer drugs (14, 26, 35, 57).  While numerous studies have shown that 
FTIs suppress oncogenic and tumor survival pathways, the actual mechanism by which 
FTIs inhibit tumor growth is not known (34, 44).  Thus, while designed originally as anti-
Ras inhibitors, the Ras isoforms most commonly mutated in human cancers (N- and K-
Ras) escape FTI inhibition by undergoing alternative prenylation by GGTase I (40, 51, 
54).  Therefore, the critical farnesylated proteins that FTIs target to induce these effects 
are not known (34, 44).  Similarly, the GGTase I substrates important for the anti-tumor 
activity of GGTIs are not clearly understood yet.  While we have implicated Rac1 and 
Rac3 Rho family proteins as candidate targets for GGTIs (22), other important targets 
remain to be identified.   Clues to what these targets may be are suggested by our 
previous studies demonstrating that GGTIs inhibit the activation of the Akt 
serine/threonine kinase and expression of survivin (10, 49).  Furthermore, GGTIs also 
induce p21waf, inhibit CDK activity, phosphorylation of Rb and lead to G0/G1 cell cycle 
accumulation (30, 35, 49-52).  In animal models, GGTIs both inhibit tumor growth in 
nude mouse xenografts and induce tumor regression in transgenic mice (48, 49). The 
GGTase I substrates targeted by GGTIs to induce their anti-neoplastic effects are not 
known.  Logical candidates include other Ras and Rho family proteins with roles in 
oncogenesis.  
Recently, the Ras-like RalA and RalB small GTPases have been shown to play 
critical roles in Ras-mediated growth transformation of human cells (16, 27).  Ral 
GTPases are activated by Ral guanine nucleotide exchange factors (RalGEFs; e.g., 
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 RalGDS), and RalGEFs function as key downstream effectors of activated Ras (38).  
Critical evidence for the important role of the RalGEF-Ral effector pathway in Ras-
mediated oncogenesis is provided by studies in cell culture and mouse model systems.  
We showed previously that this effector pathway, and not the Raf-MEK-ERK mitogen-
activated protein kinase effector pathway, is sufficient and necessary to promote Ras-
mediated tumorigenic growth transformation (16).  Similar observations were made by 
Weinberg and colleagues (36), who found cell type differences in the importance of 
RalGEF-Ral signaling in Ras transformation.  Marshall and colleagues found that mice 
deficient in one RalGEF (RalGDS) are developmentally normal, but showed impaired 
skin tumor growth caused by carcinogen-induced Ras activation (15).   An unexpected 
outcome of the study of the role of Ral GTPases in oncogenesis has been the distinct 
functions of the highly related RalA and RalB isoforms.  Although RalA and RalB share 
strong sequence (85% identity) similarities, White and colleagues found that RalA is 
important for tumor cell anchorage-independent proliferation, whereas RalB promotes 
tumor cell survival (8).  We recently determined that RalA, but not RalB is critical for 
anchorage-independent and tumorigenic growth of pancreatic carcinoma cells, whereas 
RalB and to a lesser degree RalA is critical for pancreatic carcinoma invasion and 
metastasis (28).  The distinct functions of RalA and RalB may be due, in part, to distinct 
downstream effector utilization (7, 45). 
The increasing evidence for Ral GTPases in oncogenesis prompted our interest in 
evaluating Ral GTPases as important targets for GGTI anti-tumor activity.  Both RalA 
and RalB C-termini contain a CAAX sequence that predicts prenylation, and RalA has 
been shown to be geranylgeranylated (24).  Furthermore, RalA and RalB are involved in 
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 many oncogenic steps that are inhibited by GGTIs.  Therefore, in this manuscript we 
investigated whether some of the anti-neoplastic effects of GGTIs are mediated by 
inhibition of the geranylgeranylation and function of RalA and/or RalB.  To this end, we 
have demonstrated that RalA and RalB are exclusively geranylgeranylated, generated 
farnesylated variants of Ral and verified that they are GGTI-insensitive, and used these 
variants to rescue cancer cells from the anti-neoplastic effects of GGTIs.  Our data 
suggest that inhibition of RalB mediates the effects of GGTIs on survivin, p27Kip1, 
apoptosis and anchorage-dependent growth, whereas inhibition of RalA mediates, at least 
in part, the effects of GGTIs on anchorage-independent growth.  
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 Materials and Methods 
Synthesis of CAAX Peptidomimetic—The GGTase I-specific peptidomimetics GGTI-2417 
and GGTI-2418 were synthesized as described previously (33). The FTase-specific 
peptidomimetics FTI-2148 and FTI-2153 were synthesized as described previously (48). 
Cloning of Ral A and Ral B mutants- We used our previously described RalA and RalB 
pBABE expression constructs (16) as template DNA for site directed mutagenesis PCR 
driven by Platinum Taq polymerase (Invitrogen, Carlsbad, CA) according to 
manufacturers instructions with the following primers (Qiagen, Valencia, CA): FLAG-
RalA-CCIL was generated using (F-5’GCCGGATCCATG 
GATTACAAGGATGACGACGATAAGATCGTCGACTACCTAGCAAATAAGCCC-
3’, R-5’GCCGGATCCTTATAAAATGCAGCATCTTTCTCTGATTC-3’), FLAG-RalA-
CCIS was generated using (F-5’GCCGGATCCATGGATTACAA 
GGATGACGACGATAAGATCGTCGACTACCTAGCAAATAAGCCC-3’, R-5’G 
CCGGATCCTTATGAAATGCAGCATCTTTCTCTGATTC-3’), FLAG-RalA-SCIL 
was generated using (F-5’GCCGGATCCATGGATTACAAGGATGACGACGA 
TAAGATCGTCGACTACCTAG CAAATAAGCCC-3’, R-5’GCCGGATCCTTATA 
AAATGCAGGATCTTTCTCTGATTC-3’); FLAG-RalB-CCLL was generated using (F-
5’GCCGGATCCATGGATTACAAGGATGACGACGATAAGATCGCT 
GCCAACAAGAGTAAGGGCCAG-3’, R-5’GCCGGATCCTCATAGTAAGCAA 
CATCTTTCTTTAAAACT-3’), FLAG-RalB-CCLS was generated using (F-
5’GCCGGATCCATGGATTACAAGGATGACGACGATAAGATCGCTGCCAA 
CAAGAGTAAGGGCCAG-3’, R-5’GCCGGATCCTCATGATAAGCAACATCT 
TTCTTTAAAACT-3’), FLAG-RalB-SCLL was generated using (F-5’GCCGGAT 
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 CCATGGATTACAAGGATGACGACGATAAGATCGCTGCCAACAAGAGTA 
AGGGCCAG-3’, R-5’GCCGGATCCTCATAGTAAGCAAGATCTTTCTTTAAAA 
CT-3’). These PCR fragments were subcloned into pBABE molony-murine retroviral 
plasmid by single enzyme digest with BamHI  (New England Biolabs, Ipswich, MA) 
using standard restriction enzyme conditions. Plasmid sequences were verified by 
standard Sanger sequencing reaction.  
In vitro transcription/translation/prenylation assay- Plasmid DNA was amplified in a 
PCR reaction using AccuPrime Taq polymerase (Invitrogen, Carlsbad, CA) using 1μg 
plasmid DNA by forward primer, T7-FLAG (RalA: 
5’GCCGGATCCTAATACGACTCACTATAGGGTCGACTACCTAGCAAATAAGCC
C—3’, RalB: GCCGGATCCTAATACGACTCACTATAGGGGCTGCCAAC 
AAGAGTAAGGGCCAG) and gene specific reverse primers, the same primers as 
mentioned previously in the cloning protocol. Subsequent cDNA was isolated using 
QIAquick PCR purification column (Qiagen, Valencia, CA) and 500ng was used for T7-
in vitro- transcription-translation (TnT coupled rabbit reticulocyte lysate system, 
Promega, Madison, WI). Briefly, reaction components were assembled on ice according 
to manufacturers protocol along with either 5 µCi [H3] farnesyl pyrophosphate, 5 µ Ci 
[H3]Geranylgeranyl pyrophosphate or 10 µ Ci [S35] methionine in the presence or 
absence of GGTI-2418 or FTI-2148. The reaction was incubated at 30°C for 120 min and 
the reaction was stopped by addition of an equal volume of 2x SDS-PAGE sample buffer. 
The samples were then loaded onto 12 % acrylamide SDS-PAGE gel and separated at 50 
V. Gels were then fixed in methanol/acetic acid (50% methanol, 10% glacial acetic acid, 
40 % ddH2O) for 30 min while gently shaking. Gels were then rinsed and incubated for 
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 30 min with Amplify reagent (Amersham Biosciences, Piscataway, NJ) for 30 min while 
gently shaking. Gels were then transferred to Whatman paper at 80°C for 2 h on a 
BioRad Model 583 gel drier using a BioRad HydroTech Vacuum Pump (BioRad, 
Hercules, CA). Gels were visualized by autoradiography using Kodak BioMax FX film 
(Kodak, Rochester, NY) at –80°C.  
Cells and Culture—Human tumor cell line MiaPaCa2 (pancreatic carcinoma), monkey 
embryonic kidney cell Cos7 and murine NIH-3T3 fibroblasts were purchased from 
ATCC (Manassas, VA) and grown in Dulbecco’s modified minimal essential media 
(Invitrogen, Carlsbad, CA) at 37°C in a humidified incubator at 5% CO2. 
Transfection procedure- Cells were grown to 50-70% confluence and transfected with 
Transit-LT1 (Mirus, Madison, WI) according to the manufacturer’s instructions. Briefly, 
3 μl of Transit LT1 reagent was suspended per 1 ml of OPTI-MEM media (Invitrogen, 
Carlsbad, CA) and allowed to equilibrate at 24-27°C for 15 min. Approximately 1 µg of 
plasmid per ml of media was suspended and allowed to complex with the liposomes for 
15 min at 24-27°C. Cells were briefly washed with OPTI-MEM and 2 ml containing 2 µg 
media and 6 µl Transit LT1 was plated on top of the cells and incubated at 37°C for 6 h. 
Two ml of DMEM containing 10% FBS, without penicillin-streptomycin, was added and 
the cells were further incubated at 37°C overnight. 
Immunofluorescence- Cos7 cells were seeded at a 50% cell density in 6-well plates 
containing sterilized glass coverslips and allowed to attach overnight. Cells were 
transfected overnight using TransitLT1 in Opti-MEM media following the 
manufacturer’s instructions. Media was replaced with complete growth media containing 
either DMSO, 25 µM FTI-2153 or 25 µM GGTI-2417 and incubated at 37°C, 5% CO2 
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 for 48 h. Cells were then aspirated and washed twice with sterile PBS (pH 7.4) and fixed 
in 4% paraformaldehyde. Cells were then rinsed twice with sterile PBS (pH 7.4) and 
permeabilised, on ice, with 0.1% Triton X-100. Cells were then blocked for one hour 
with 1% BSA, rinsed twice and incubated overnight with 1:100 anti-FLAG M2 
monoclonal antibody (Sigma-Aldrich, St. Louis, MO) or 1:100 anti-Hemaglutin (HA) 
monoclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA). Cells were rinsed 
three times in sterile PBS (pH 7.4) and then incubated for one hour with secondary 
antibody, FITC-conjugated rabbit anti-mouse (Santa Cruz Biotechnology, Santa Cruz, 
CA). Cells were then washed twice in sterile PBS, mounted using Vectashield mounting 
reagent containing DAPI for nuclear visualization and analyzed using a Leica DMIL 
florescent microscope (Leitz, Wetzlar, Germany) at 525 nm (FITC) and 365/420 nm 
DAPI. 
Luciferase assay – NIH-3T3 cells were plated (106 cells well) in 6-well plates and 
transfected using standard  calcium phosphate-mediated transfection with 4 µg of either 
pBABE, HA-H-Ras12V, FLAG-RalA72L-F, FLAG-RalA72L-GG, FLAG-RalA72L-S, 
FLAG-RalB72L-F, FLAGRalB72L-GG, or FLAG-RalB72L-S; 1 µg of NF-KB-pTAL 
firefly luciferase plasmid (BD Biosciences, Franklin Lakes, NJ); and 0.2 µg Renilla 
luciferase plasmid for 5 h (both from BD Biosciences, Franklin Lakes, NJ). Cells were 
then incubated in full growth media overnight followed by serum starvation for 24 h  in 
DMEM supplemented with 0.5% fetal calf serum. Cells were then lysed, and luciferase 
activity was determined using ProMega dual luciferase assay system according to the 
manufacturer’s instruction. 
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 Western blotting—Cells were treated with GGTI-2417 for 48 h, harvested, and lysed in 
HEPES lysis buffer as described previously (51). Proteins were then resolved by 12.5% 
SDS-PAGE and immunoblotted with antibodies against unprenylated Rap1A/Krev-
1(121), p21WAF1 (C-190), Akt 1-2 (N19), and RhoB (119), RhoA (26C4), anti-
Hemaglutin (HA) monoclonal antibody and survivin (FL142) (all from Santa Cruz 
Biotechnology, Santa Cruz, CA), p27KIP1 (G173–524), (from Pharmingen, San Diego, 
CA), phospho-serine 473 Akt (Cell signaling, Danvers, MA) and β-actin (AC15) and 
anti-FLAG M2 monoclonal antibody (both from Sigma-Aldrich, St. Louis, MO). The 
ECL blotting system (NEN Life Science Products, Boston, MA) was used for detection 
of positive antibody reactions. 
Trypan blue dye exclusion assay- Adherent cells were harvested using trypsinisation and 
pooled with suspension cells from media supernatant by pelleting at 300g for 5 min at 
4°C. The cells were then aspirated and resuspended in an appropriate volume of media by 
pipetting gently up and down. Two 20 µl aliquots were removed and combined with an 
equal volume of trypan blue and allowed to mix for 2 min. A 10 µl volume was loaded 
onto a hemacytometer and cells were scored as live or dead based on trypan blue dye 
exclusion. 
TUNEL analysis- Cells were seeded into 60-mm-diameter dishes and grown in DMEM 
supplemented with 5% FCS for 24 h and then treated with GGTI-2417 for 48 h, which 
we determined to be the optimal timepoint for induction of apoptosis. Apoptosis was 
determined by terminal deoxynucleotidyltransferase-mediated dUTP nick end labeling 
(TUNEL) by using an in situ cell death detection kit (Roche, Indianapolis, IN). The cells 
were trypsinized, and cytospin preparations were obtained by centrifugation at 1,500xg 
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 (using a Cytospin-3 centrifuge, Therma-Shandon) Cells were fixed with freshly prepared 
paraformaldehyde (4% in phosphate-buffered saline [PBS], pH 7.4). Slides were rinsed 
with PBS, incubated in permeabilization solution, and cross-reacted with TUNEL 
reaction mixture for 60 min at 37°C in a humidified chamber. The slides were rinsed, 
mounted and analyzed under a light microscope.  
Creation of retrovirus- Retrovirus was created by transient transfection of HEK-293T 
human embryonic kidney cells with pVPACK-Ampho, pVPACK-gag-pol and pBABE 
retroviral plasmids according to manufacturers protocol (Invitrogen Carlsbad, CA). 
Briefly 293T cells were seeded at 2.5x106 cells in a 60 mm2 dish. 3 µg of each plasmid 
was combined and brought to a volume of 225 µl in Rnase/Dnase free water following 
which 25 µl 2.5 M CaCl2 was added dropwise while gently vortexing. This solution was 
then added to 250 µl 2x Hepes-buffered saline dropwise and incubated at room 
temperature for 5 min. The total volume of 500 µl was then added to the 293T cells and 
incubated for 8 h at 37°C. The medium was then removed and cells were incubated for 48 
h. The supernatant was then passed through a 0.45 µM nylon low protein-binding filter 
(Fisherbrand, Houston, TX) to remove cells and cell debris. Retroviral titers were 
determined by serial dilution and infection of NIH-3T3 cells followed by selection and 
colony formation in puromycin. 
Cellular fractionation – Membrane and cytosolic fractions were isolated using the MEM-
PER membrane extraction kit (Promega, Madison, WI).  Briefly, 1x106 Cos7 cells were 
transfected with the appropriate plasmid and collected seventy-two hours later.  Cells 
were lysed and membrane and cytosolic fractions were isolated according to 
manufacturer’s protocol.  Membrane and cytosolic fractions were diluted five fold and 
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 diluted further in 2x Laemmli sample buffer (Biorad, Carlsbad, CA).  Proteins were 
separated by SDS-PAGE and visualized by Western blotting.  
Creation of stable cell lines- MiaPaCa2 cells were seeded into 6-well plates at a 40% 
confluency and incubated with 8 µg/ml polybrene (Millipore/Specialty Media, Billirika, 
MA) and 5x105 viral particles for 8 h. Medium was changed to complete growth media 
and cells were incubated at 37°C, 5% CO2 for 24 h. Media was then replaced with 
complete growth media containing 4 µg/ml puromycin and incubated until colonies 
formed. All colonies were pooled and taken as a single polyclonal population and 
cultured in complete media containing 2 µg /ml puromycin.  
MTT metabolism assay- Cells were seeded in a 96-well plate at a density of 1,500 cells 
per well and allowed to attach overnight. Cells were then incubated for 96 h with varying 
concentrations of GGTI-2417 or appropriate DMSO control. Media was aspirated after 
96 h, the optimal time for study of proliferation using this assay, and replaced with 
complete medium containing 1 mg/ml MTT and incubated for 3 h at 37°C in 5% CO2 
humidified incubator. Medium was then aspirated and DMSO was added. Cells were 
incubated 5 min at room temperature while shaking following which absorbance was 
determined at 495 nm.  
Soft agar clonogenicity assay- For soft agar growth assays, the cell lines were seeded at a 
cell density of 1,500/well in triplicate in 12-well culture dishes in 0.3% agar over a 0.6% 
bottom agar layer. Various concentrations of GGTI-2417 or vehicle (DMSO) were 
included in the 0.3% agar layer of cells. Cultures were fed and treated with drug or 
vehicle once weekly until colonies grew to a suitable size for observation (colony growth 
rates were 10-14 days for RalA stable MiaPaCa2 cells and 3 weeks for RalB stable 
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 MiaPaCa2 cells). Colonies were photographed after overnight incubation with 1 mg/ml 
MTT in the respective cell growth media. The growth of colonies in the presence of 
inhibitor was compared with the control colonies treated with vehicle. 
Statistical analysis- Statistical analysis was performed using standard student’s T-Test 
via either Microsoft Excel (Microsoft, Redmond, WA) or GraphPad Software (San 
Diego, CA) statistical analysis tools.  
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 Results 
Generation of CAAX box mutants that are farnesylated or unprenylated versions of 
both RalA and RalB  
It has been demonstrated previously that RalA is geranylgeranylated and that both 
RalA and RalB require the prenyl-accepting cysteine for proper localization (18, 24). 
However, direct evidence that RalA and RalB are exclusively geranylgeranylated, and 
thus validated targets of GGTI’s, is lacking.  Furthermore, whether the nature of the 
prenyl group influences the subcellular location and function of Ral proteins is not 
known.  To this end, we used site-directed mutagenesis to generate two CAAX box 
mutant forms of wild type or GTPase-deficient /constitutively activated (Q72L) RalA and 
RalB proteins. The first missense mutation replaced the carboxyl-terminal leucine with a 
serine residue to switch the prenyltransferase specificity from GGTase I (RalA-CCIL and 
RalB–CCLL) to a site preferred by the related enzyme FTase (RalA–CCIS and RalB–
CCLS).    The second mutation replaced the prenylated cysteine with a serine residue to 
prevent prenylation (RalA SCIL and RalB- SCLL).  Both GTP-locked (RalA72L, 
RalB72L) and wild type RalA and RalB were used to generate the CAAX box mutants.  
Plasmid constructs containing these Ral cDNA sequences were then used in in vitro 
transcription-translation-prenylation assays in rabbit reticulocyte lysates with 
radiolabeled [35S]-labeled-methionine, [3H]-labeled farnesyl pyrophosphate (FPP) and 
[3H]-labeled geranylgeranyl pyrophosphate (GGPP) to determine the relative strength of 
translation, farnesylation and geranylgeranylation, respectively.  Figure 5A (see 
following pages) shows that RalA–CCIL and RalB-CCLL were geranylgeranylated while 
replacement of the carboxyl-terminal amino acid with a serine resulted in incorporation 
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 of a farnesyl instead of a geranylgeranyl moiety. Replacement of the prenylation site 
cysteine with a serine residue (CCIL and CCLL to SCIL and SCLL) rendered both RalA 
and RalB unprenylated (Figure 5A, following pages).  
62
 Geranylgeranylated and farnesylated RalA and RalB are not alternatively 
prenylated in the presence of GGTIs and FTIs, respectively. 
It has been well documented that certain Ras family members are capable of 
being alternatively prenylated when FTase is inhibited (40, 51, 54). We reasoned that it is 
possible that RalA and/or RalB (geranylgeranylated or farnesylated forms) could be 
alternatively prenylated when GGTase I or FTase is inhibited. In order to determine 
whether the wild type RalA-CCIL and RalB-CCLL were indeed targets only of GGTase I 
and could not be prenylated by FTase upon GGTase I inhibition, we added GGTI-2418, a 
potent and selective competitive inhibitor of GGTase I (33), to the reticulocyte lysate 
transcription-translation-prenylation mixture (Figure 5B, following pages). Wild type 
RalA-CCIL and RalB-CCLL were geranylgeranylated and were not alternatively 
farnesylated when GGTase I was inhibited by GGTI-2418, and their geranylgeranylation 
was little affected by inhibition of FTase by our previously characterized FTase-specific 
inhibitor, FTI-2148 (48). Furthermore, RalA-CCIS and RalB-CCLS remained 
farnesylated when GGTase I was inhibited and did not become geranylgeranylated when 
FTase I was inhibited (Figure 5B, following page).  Minor variations in the apparent 
incorporation efficiency of the radiolabeled prenyl groups in the absence or presence of 
inhibitors, was seen regularly but without consistency.  These results suggest that RalA-
CCIL and RalB-CCLL are targets of GGTIs but not FTIs, and conversely, that the RalA-
CCIS and RalB-CCLS CAAX box mutants are targets of FTIs, but not GGTIs.  
Furthermore, neither the geranylgeranylated or farnesylated Ral proteins are alternatively 
prenylated under the pressure of GGTI or FTI treatment, respectively.  Therefore, for the 
rest of the manuscript we will refer to RalA-CCIL and RalB-CCLL as RalA-GG and 
63
 RalB-GG, respectively.  Similarly, we will refer to RalA-CCIS and RalB-CCLS as RalA-
F and RalB-F, respectively. 
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Figure 5. RalA-CCIL and RalB-CCLL are geranylgeranylated whereas the 
mutants RalA-CCIS and RalB-CCLS are farnesylated. A) Ral DNAs were 
used in transcription-translation-prenylation assays using either radiolabeled
[35S]-methionine, [3H]-FPP or [3H]-GGPP then run on SDS-PAGE and 
visualized by autoradiography as described in Materials and Methods. Results 
are representative of two independent experiments. B) RalA-CCIS, RalA-CCIL, 
RalB- CCLS or RalB-CCLL DNAs were transcribed, translated and prenylated 
using either [35S]-Methionine, [3H]-FPP or [3H]-GGPP in the presence of either 
vehicle (DMSO), 250 nM FTI-2148 or 250 nM GGTI-2418 then run on SDS-
PAGE and visualized by autoradiography. Results are representative of two 
independent experiments. 
Figure 5. RalA-CCIL and RalB-CCLL are geranylgeranylated whereas the 
mutants RalA-CCIS and RalB-CCLS are farnesylated
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 Prenylation is required for proper subcellular localization of RalA and RalB and 
both RalA and RalB are mislocalized in response to prenyltransferase inhibition.  
 The results of Figure 1 demonstrated, in a reconstituted cell reticulocyte system, 
that the wild type RalA-GG, RalB-GG, and CAAX box mutant RalA-F and RalB-F 
variants are not alternatively prenylated in vitro.  We next determined whether 
prenylation is required for proper localization in intact cells and whether GGTI-2417 
treatment is sufficient to disrupt localization of wild type RalA-GG and RalB-GG. We 
also wanted to determine if the RalA-F and RalB-F mutants display a localization similar 
to RalA-GG and RalB-GG.  To this end, we ectopically expressed FLAG epitope-tagged 
RalA-GG, RalA-F, RalA-S, RalB-GG, RalB-F or RalB-S in Cos-7 cells followed by 
treatment with the indicated prenyltransferase inhibitors.  We found that both the 
geranylgeranylated and farnesylated forms of RalA and RalB demonstrated a similar 
localization to the plasma membrane (Figure 6, following pages).  This was confirmed by 
membrane/cytosol cellular fractionations where RalA-GG and RalB-GG as well as RalA-
F and RalB-F localized to the membrane fractions (Figure 7A, following pages).  The fact 
that RalA and RalB localize similarly is interesting but different than results by Feig et al 
(45).  The reason for this difference at present is not known.  The unprenylated versions 
of RalA (RalA-S) and RalB (RalB-S) were diffused in the cytoplasmic and the 
perinuclear regions indicating that prenylation is required for proper plasma membrane 
localization of RalA and RalB (Figure 6, following pages). Furthermore, in response to 
GGTase I inhibition RalA-GG and RalB-GG were unable to localize to the plasma 
membrane while no change in membrane localization was observed when FTase activity 
was inhibited. As expected, H-Ras was predominantly localized to the plasma membrane, 
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 and this was only affected by FTI but not GGTI treatment.  Similarly, in response to 
FTase inhibition, RalA-F and RalB-F were unable to localize to the plasma membrane 
while no change in membrane association was observed when treated with GGTase I 
inhibition (Figure 6, following pages). These data demonstrate that RalA-GG and RalB-
GG are targets of GGTase I inhibitors and that the farnesylated Ral variants will be useful 
reagents to determine if inhibition of Ral GTPases contribute to the biological effects of 
GGTI-2417 treatment.  
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Figure 6. Geranylgeranylated (GG) and farnesylated (F) RalA and RalB 
localize similarly and require prenylation for correct localization. Cos7 
cells grown on coverslips were transiently-transfected with plasmids 
expressing the indicated proteins and treated with the indicated inhibitors 
(25μΜ), and were then analyzed for FLAG-Ral or HA-H-Ras distribution 
using immunoflorescence as described under Materials and Methods. Nuclei 
were visualized using DAPI stain. Results are representative of three 
independent experiments. 
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 Farnesylated and geranylgeranylated RalA and RalB are equivalent in ability to 
activate NF-ΚB responsive promoter elements  
 We next wanted to verify that Ral function was retained when modified by 
farnesylation.  It has been reported previously that the constitutively activated RalB72L 
mutant protein is capable of activating NF-ΚB-dependent transcription (17).  We 
therefore determined if farnesylation and geranylgeranylation of Ral are equivalent in 
their ability to mediate Ral activation of an NF-ΚB -dependent promoter. In order to 
assess the contribution of the prenyl moiety to NF-κB-driven transcription we transiently 
transfected NIH-3T3 cells with either the pBabe-puro empty vector, or encoding 
constitutively activated H-Ras (H-Ras12V), RalB72L-GG, RalB72L-F, RalB72L-S, 
RalA72L-GG, RalA72L-F or RalA72L-S. As expected, H-Ras12V stimulated an 
approximately four-fold increase in NF-ΚB luciferase activity (Figure 7, following page). 
As previously reported, RalB72L-GG activated NF-ΚB-dependent promoter activity. 
Importantly, RalB72L-F activated NF-ΚB luciferase activity to a similar extent as the 
geranylgeranylated version (approximately two-fold). Similar to the results with RalB, 
ectopic expression of RalA72L-GG and RalA72L-F both stimulated four-fold activation 
of NF-ΚB. Importantly, neither nonprenylated RalB-S nor RalA-S stimulated activation 
of NF-ΚB (Figure 7, following page). These data demonstrate that prenylation is required 
for RalA and RalB activation of NF-ΚB and that farnesyl and geranylgeranyl moieties are 
equivalent in supporting Ral activation of NF-ΚB.    
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Figure 7. Farnesylated and geranylgeranylated RalA and RalB are 
equivalent in mediating activation of NF-κB promoter activity. A) 
Cos7 cells were transiently transfected with the indicated plasmids and 
membrane (M) and cytosolic (C) fractions were isolated and probed by 
Western blotting; HSP90 was used as a cytosolic fraction marker.  Results 
are representative of 2 independent experiments.  B) NIH-3T3 cells were 
serum-starved and transiently co-transfected with plasmid expressing the 
indicated proteins and a NF-κB reporter plasmid. NF-κB promoter 
activity was detected following transfection as described under Materials 
and Methods. Expression was analyzed by western blot analysis. Results 
are representative of three independent experiments. 
Figure 7. Farnesylated and geranylgeranylated RalA and RalB are 
equivalent in mediating activation of NF-κB promoter activity.
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 Ectopic expression of RalB-F renders Cos7 cells resistant to inhibition of 
proliferation, induction of cell death and apoptosis by GGTI-2417  
Since the farnesylated and geranylgeranylated forms of Ral proteins displayed 
similar subcellular localization and signaling properties, we reasoned that, if Ral GTPases 
are important functional targets of GGTIs, ectopic expression of farnesylated, but not 
geranylgeranylated, RalA and/or RalB would rescue cells from the effects of GGTase I 
inhibition. Figure 8A (see following pages) shows that ectopic expression of farnesylated 
RalB, but not RalA, rendered cells less sensitive to the induction of cell death by GGTI-
2417. There were no statistically significant differences between all transfected groups 
(pBabe empty vector control, RalA-F, RalA-GG, RalB-GG) in cell death except in the 
RalB-F expressing Cos7 cells (P<0.05 at 50, 100 and 150 μM). For example, GGTI-2417 
induced 39% cell death at 50 μM in RalB-GG transfected Cos7 cells but when RalB-F 
was expressed GGTI-2417 induced only 7 % cell death (Figure 8A, following pages). 
Similarly, RalB-F expressing Cos7 cells were 4.51-fold more resistant to inhibition of 
proliferation by GGTI-2417 than RalB-GG expressing cells (IC50 of 131 μM and 29 μM, 
respectively) (Figure 8B, following pages).  
 We next determined whether RalA-F and/or RalB-F could rescue cells from 
GGTI-2417 treatment-induced programmed cell death (apoptosis) by TUNEL assay. 
Figure 8D (see following pages) shows that only ectopic expression of farnesylated RalB, 
but not farnesylated RalA, demonstrated a significantly protective effect from GGTI-
2417-induced apoptosis.   GGTI-2417 increased the fraction of apoptotic cells from about 
18 to 32% in RalB-GG but only from 17 to 20% in RalB-F (Figure 8D, following pages).  
In contrast, GGTI-2417 potently induced apoptosis in Cos7 cells expressing either RalA-
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 GG or RalA-F, with GGTI-2417 treatment increasing the fraction of apoptotic cells from 
approximately 15% to 30% in both cell populations (Figure 8D, following pages).  These 
results suggest that inhibition of RalB and not RalA geranylgeranylation is an important 
target for GGTI-mediated apoptosis.  All cell lines displayed similar accumulation of 
non-geranylgeranylated Rap1A following GGTI-2417 treatment (Figure 8C, following 
pages).  No changes were observed in gel mobility of the human homologue of DNAJ-2 
(HDJ2), an exclusively farnesylated protein, indicating that FTase activity was not 
blocked by this treatment (Figure 8C, following pages). 
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cells less sensitive to GGTI-2417 inhibition of survival and proliferation and 
induction of apoptosis in Cos7 cells
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Figure 8. Ectopic expression of farnesylated RalB, but not RalA, renders 
cells less sensitive to GGTI-2417 inhibition of survival and proliferation 
and induction of apoptosis in Cos7 cells. A-B) Inhibition of RalB 
prenylation is required for GGTI induction of cell death and inhibition of 
proliferation. Cos7 cells were transfected with the indicated plasmids then 
treated with GGTI-2417 or vehicle (DMSO) control. Cell viability was 
determined by the trypan blue dye exclusion assay. Data shown are the 
average of three independent experiments. C) Cell lysates from A-B were 
analyzed for expression by western blot analysis as described in Materials 
and Methods. D) Inhibition of RalB prenylation is required for GGTI 
induction of apoptosis.  Cos7 cells were transiently-transfected with plasmids 
expressing the indicated proteins and then treated for 72 h with 50 μM GGTI-
2417 or DMSO control, collected and analyzed for apoptosis via TUNEL 
assay as described in Materials and Methods. Data shown are the average of 
three independent experiments. (*p<0.05)
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 MiaPaCa2 human pancreatic cancer cells stably expressing farnesylated RalB are 
resistant to the anti-proliferative and pro-apoptotic effects of GGTI-2417 compared 
to geranylgeranylated RalB-expressing cells   
Since Cos7 are immortalized non-transformed cells of non-human primate origin 
we endeavored to create a more relevant cell system to characterize the growth inhibitory 
and pro-apoptotic effects of GGTI-2417. We first determined by western blotting that 
both RalA and RalB are efficiently targeted by GGTI-2417 in MiaPaCa2 cells. Figure 9A 
(see following pages) shows that GGTI-2417 concentrations as low as 1μΜ inhibited 
RalA and RalB geranylgeranylation.  We next established populations of MiaPaCa2 cells 
stably expressing RalA and RalB prenyl isoforms through retroviral transduction and 
selection (Figure 9B, following pages).  We then used these cells to examine the effects 
of ectopic WT or farnesylated RalA and RalB expression on GGTI-2417-mediated 
inhibition of proliferation of MiaPaCa2 cells by both MTT metabolism viability (Figure 
9C) and trypan blue dye exclusion assays (Figure 9D, following pages). Similar to our 
observations in Cos7 cells, MiaPaCa2 cells stably expressing farnesylated as opposed to 
geranylgeranylated RalB were less sensitive to the anchorage-dependent anti-proliferative 
effects of GGTI-2417.  Specifically, using the MTT assay RalB-GG expressing cells 
were inhibited by 50% at 1.6+/- 0.3 μM GGTI-2417 whereas RalB-F expressing cells 
(IC50 of 8.3 ± 1.4 μM, p value = 0.0015) were more than 5-fold resistant. There were no 
statistically significant differences between RalB-GG and empty vector cells.  
Furthermore, no statistically significant differences in proliferation inhibition sensitivity 
were observed for empty vector, RalA-F or RalA-GG expressing cells (Figure 9C, 
following pages). Similar results were obtained using total cell counting by trypan blue 
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 dye exclusion assay demonstrating no difference in sensitivity between RalA-F and 
RalA-GG expressing cells and a greater than 6-fold statistically significant difference 
(p<0.0001) in IC50 values between RalB-GG and RalB-F expressing cells (IC50 values 
of 4.8 ± 1.6 μM and greater than 30 μM, respectively) (Figure 9D, following pages).  
There were no statistically significant differences between empty vector (5.6 ± 1.7 μΜ) 
and RalB-GG (4.8 ± 1.6 μM) cells.  These data both confirmed and extended our 
observations in Cos7 cells and further indicated that inhibition of RalB, not RalA, 
prenylation is an important target for GGTI inhibition of anchorage-dependent cell 
proliferation.  
To further examine the role of Ral proteins in GGTI-2417 induction of apoptosis, 
we determined if ectopic expression of RalA-GG, RalA-F, RalB-GG or RalB-F altered 
MiaPaca2 sensitivity.  Specifically, we observed that GGTI-2417 treatment induced a 
greater than three-fold increase in apoptosis in all cell lines except those expressing 
RalB-F (Figure 9F, following pages).  Of primary importance, GGTI-2417 induced a 3.6-
fold induction of apoptosis (1.6 to 6.07%) in RalB-GG expressing cells as compared to 
no statistically significant induction of cell death in RalB-F expressing cells (1.42 to 
1.56%). This indicates that, consistent with the Cos7 results, RalB and not RalA is a 
critical target for the apoptotic cell death caused by GGTI-2417 treatment of MiaPaCa2 
cells.  
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promotes resistance to the anti-proliferative and pro-apoptotic effects 
of GGTI-2417 in MiaPaCa2 cells.
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Figure 9. Stable expression of farnesylated RalB, but not RalA, promotes 
resistance to the anti-proliferative and pro-apoptotic effects of GGTI-
2417 in MiaPaCa2 cells. A) Dose response to determine the efficacy of 
GGTI-2417 in inhibiting RalA and RalB prenylation in MiaPaCa2 cells. 
MiaPaCa2 cells were treated with various concentrations of GGTI-2417 for 
48h and processed for Western blotting as described under Materials and 
Methods. B) Stable MiaPaCa2 cell lines were created using retroviral 
infection of puromycin resistance marker along with the indicated transgenes
as described under Materials and Methods. Cells were lysed and expression 
was assessed by western blot analysis. C) Stably expressing MiaPaCa2 cells 
were treated with the indicated concentrations of GGTI-2417 for 96 h. 
Proliferation was measured by the MTT viability assay as described in 
Materials and Methods.  Data shown are the average of at least three 
independent experiments.  D) MiaPaCa2 cells stably expressing the indicated 
Ral proteins were treated with the indicated concentrations of GGTI-2417 for 
72 h. Proliferation was assessed by trypan blue dye exclusion assay as 
described in Materials and Methods. Data shown are the average of at least 
three independent experiments. E) MiaPaCa2 cells stably expressing the 
indicated Ral proteins were treated with GGTI-2417 (30μΜ), lysed and 
expression was assessed by western blot analysis. Data shown are
representative of three independent experiments. F) MiaPaCa2 cells stably 
expressing the indicated Ral proteins were treated with GGTI-2417 for 48 h 
and apoptosis was assessed by TUNEL assay as described in Materials and 
Methods. Data shown are the average of three independent experiments.  (*, 
p<0.05; **, p<0.01, ***,p<0.001)
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 Stable expression of farnesylated RalA, but not RalB, induces partial resistance to 
inhibition of anchorage-independent growth by GGTI-2417 in MiaPaCa2 cells   
We next determined whether GGTI-2417 inhibition of growth in soft agar might 
be due, in part, to inhibition of RalA and/or RalB function.  To this end, we used a soft 
agar clonogenicity assay to measure the effects of GGTI-2417 on MiaPaCa2 cells stably 
expressing geranylgeranylated or farnesylated RalA or RalB.  We found that MiaPaCa2 
cells stably expressing either RalB-GG or RalB-F did not differ in sensitivity to GGTI-
2417 treatment. However, MiaPaCa2 cells stably expressing RalA-F were less sensitive 
to inhibition of soft agar growth by GGTI-2417 than those cells stably expressing ectopic 
RalA-GG (Figure 10, following page). For example, at 30μΜ GGTI-2417, RalA-GG and 
RalA-F inhibited colony formation by 41.3 ± 5.9 and 17.8 ± 8.0, respectively (p<0.001). 
Taken as a whole these data implicate RalA, but not RalB, inhibition of prenylation as a 
potential mechanism for GGTI reversion of the transformed growth phenotype of 
MiaPaCa2 cells as measured by anchorage-independent soft agar growth.  
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Figure 10. Stable expression of farnesylated RalA, but not RalB, 
induces resistance to inhibition of anchorage independent growth by 
GGTI-2417 in MiaPaCa2 cells. MiaPaCa2 cells stably-expressing the 
indicated Ral proteins were seeded into 12-well plates in 0.3% soft agar and 
treated with the indicated concentrations of GGTI-2417 for 10 days as 
described in Material and Methods. Data shown are the average of two 
independent experiments repeated in triplicate.  (*, p<0.05; ***,p<0.001 )
Figure 10. Stable expression of farnesylated RalA, but not RalB, induces 
resistance to inhibition of anchorage independent growth by GGTI-2417 
in MiaPaCa2 cells. 
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 Stable expression of farnesylated RalB but not RalA in MiaPaCa2 cells inhibits the 
ability of GGTI-2417 to increase p27Kip1 and decrease survivin protein levels.   
  Recent data from our lab showed that GGTIs treatment affects several signal 
transduction pathways critical to cell cycle division and tumor cell survival (30, 35, 49-
52)1.  In order to examine the contribution of inhibition of the geranylgeranylation of 
RalA and/or RalB to the effects of GGTI-2417 on signaling pathways, we treated 
MiaPaCa2 cells stably expressing RalA-GG, RalA-F, RalB-GG and RalB-F with GGTI-
2417. In control, empty vector-transfected MiaPaCa2 cells, GGTI-2417 treatment 
resulted in inhibition of RalA and Rap1 geranylgeranylation, increased the protein levels 
of p27Kip1, RhoA and RhoB and decreased the levels of two anti-apoptotic proteins, 
activated phosphorylated Akt (P-Akt) and survivin (Figure 11, following page).   
Expression of RalA-F, RalA-GG, or RalB-GG did not affect the ability of GGTI-2417 to 
induce its effects on these signaling molecules. However, expression of RalB-F inhibited 
the ability of GGTI-2417 to increase p27Kip1 and to decrease survivin protein levels.  
For example, while p27Kip1 protein levels were increased in cells expressing RalB-GG 
(3.12 ± 0.88 fold) cells expressing RalB-F showed a 50% (1.63 ± 0.64 fold) attenuated 
increase of p27Kip1 protein levels (p=0.0073). Furthermore, GGTI-2417 treatment 
reduced survivin levels by 46 ± 11% in empty vector and RalB-GG expressing cells. 
However, MiaPaCa2 cells expressing RalB-F were less sensitive to depletion of survivin 
levels, with only a 12 ± 3% reduction of survivin levels following GGT-2417 treatment 
(p=0.0006). By contrast expression of either RalA-F or RalA-GG had no effect on GGTI 
                                                 
1 and Kazi A, A Carie, MA Blaskovich, C Bucher, V Thai, S Moulder, H Peng, D 
Carrico, E Pusateri, AD Hamilton and SM Sebti, Inhibition of Protein 
Geranylgeranylation Requires p27Kip1 to Induce Human Breast Cancer Cell Death: 
Implications for breast cancer therapy, submitted for publication. 
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 reduction of survivin or induction of p27Kip1. To determine if knockdown of RalA or 
RalB affects the levels of survivin or p27Kip1, we used siRNA to specifically inhibit 
RalA and RalB expression in parental MiaPaCa2 cells. We found that knockdown of 
RalB, but not RalA, inhibited the survivin protein levels by 70.2%, whereas neither RalA 
nor RalB knockdown affected the levels of p27Kip1 (data not shown).  
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Figure 11. RalB-F, not RalA-F, inhibit the ability of GGTI-2417 to 
increase p27Kip1 and decrease survivin protein levels. Stably expressing 
MiaPaCa2 cells were seeded into 6-well plates and treated with GGTI-2417 
(30μΜ) for 48 h. Cells were lysed and expression was assessed by western blot 
analysis. Data shown are representative of three independent experiments.
Figure 11. RalB-F, not RalA-F, inhibit the ability of GGTI-2417 to 
increase p27Kip1 and decrease survivin protein levels. 
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 Discussion 
 Inhibition of protein geranylgeranylation strongly attenuates multiple tumorigenic 
pathways such as anchorage-dependent and –independent tumor growth and protection 
from apoptosis (30, 35, 49-52).   However, many proteins are substrates for GGTase I-
mediated protein geranylgeranylation, and it is not known which of these are critical 
targets for the anti-neoplastic effects of GGTIs (56). Since recent studies demonstrated 
the important roles of the RalA and RalB small GTPases in human oncogenesis (7, 8, 15, 
16, 28, 36, 38, 45), we evaluated the possibility that these GGTase I substrates are 
important targets for GGTIs.  In this study we have demonstrated that the GTPases RalA 
and RalB are geranylgeranylated by GGTase I, require prenylation for proper localization 
and are downstream targets of pharmacological inhibitors of GGTase I.  We designed 
farnesylated, GGTI-insensitive, variants of Ral GTPases and found that farnesylated 
RalB, but not RalA, confers resistance to the pro-apoptotic and anti-anchorage-dependent 
growth effects of GGTI-2417 on Cos7 and MiaPaCa2 pancreatic carcinoma cells.  
Conversely, farnesylated RalA, but not RalB expression renders MiaPaCa2 cells less 
sensitive to inhibition of anchorage-independent growth. Finally, we determined that 
farnesylated RalB, but not RalA inhibited the ability of GGTI-2417 to suppress survivin 
and induce p27Kip1. We conclude that RalA and RalB are important, functionally 
distinct targets for GGTI-mediated anti-neoplastic effects.  Additionally, our studies 
extend recent observations showing that the highly related RalA and RalB proteins serve 
distinct functions in oncogenesis.   
The determination of the GGTase I substrates that are critical for the anti-tumor 
activity of GGTIs is complicated by the fact that over 60 CAAX-terminating proteins 
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 may be substrates for this prenyltransferase (56). We previously established and validated 
a substitutive chemical biology approach to define the contribution of inhibition of 
specific GGTase I substrates to GGTI inhibition of cell survival, proliferation, 
transformation and cell signaling (22). In this study, we applied this approach and we 
generated farnesylated mutants of both RalA and RalB and showed that they localized 
similarly to authentic geranylgeranylated wild-type versions and similarly activated NF-
κB and were resistant to inhibition by GGTI treatment. Thus, this substitutive chemical 
biology approach is a valid means of uncoupling RalA and RalB from GGTase I 
dependency while preserving their wild type subcellular localization and signaling 
activity.    
Our results demonstrate a partial requirement for inhibition of RalA prenylation in 
the inhibition of anchorage-independent growth by GGTI-2417. Since expression of 
farnesylated RalB did not attenuate the ability of GGTI-2417 to inhibit anchorage-
independent growth we reason that the ability of RalA to regulate clonogenecity is a 
divergent function from that of the 85% identical protein RalB. The ability of 
farnesylated RalA but not RalB to regulate anchorage-independent growth is similar to 
results reported by Chien et al (15) where depletion of RalA but not RalB by siRNA 
inhibited anchorage independent growth in HeLa and SW480 cancer cell lines. However, 
other processes commonly associated with anchorage-independent proliferation such as 
cell migration and chemotaxis bear a requirement for RalB as opposed to RalA; such 
results were first reported by Oxford et al (32) where depletion of RalB but not RalA by 
siRNA inhibited cell migration in a panel of renal carcinoma cell lines.  In particular, we 
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 found that RNAi-mediated suppression of RalA, but not RalB greatly impaired the soft 
agar growth of MiaPaCa2 and other pancreatic carcinoma cells (27, 28).  
Interestingly, we found further divergent functions for the Ral family of small 
GTPases. Specifically, inhibition of RalB, but not RalA, prenylation was required for 
GGTI-mediated inhibition of proliferation and induction of apoptosis. In both the Cos7 
and the MiaPaCa2 cell lines expression of RalB-F but not RalA-F rendered cells less 
sensitive to GGTI-mediated inhibition of proliferation and induction of apoptosis. In 
MiaPaCa2 cells this rescue was concurrent to abrogation of GGTI effects on increasing 
p27Kip1 and decreasing  survivin protein levels, but not on inhibiting Akt activation 
levels and inducing RhoA and RhoB levels, both of which we have shown previously to 
be induced by GGTIs (11). These results suggest that, at least in the MiaPaCa2 pancreatic 
carcinoma cells, the ability of RalB-F to abrogate the GGTI anti-proliferative and pro-
apoptotic mechanism of action is associated with abrogation of p27Kip1 induction and 
suppression of survivin levels.  In further support of this we used siRNA to specifically 
inhibit RalA and RalB expression and found that knockdown of RalB, but not RalA, 
strongly attenuated survivin expression but did not affect p27Kip1 levels.  These results 
concur with previous data that some tumor cells have at least a partial requirement for 
RalB in suppressing apoptosis (8) and suggest that RalB maintenance of survivin 
expression could be an important mechanism by which RalB promotes tumor cell 
survival. These results agree with our previous finding that ectopic expression of survivin 
partially abrogates GGTI induction of programmed cell death (10).   Taken as a whole the 
results of this study raise interesting questions about the mechanism of GGTI-mediated 
anti-neoplastic activity. Both RalA and RalB are important regulators of many cellular 
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 processes that have not previously been implicated in the GGTI mechanism of action. 
One of the most critical of these in oncogenesis is cellular trafficking both at the receptor 
level through endocytosis and through formation and delivery of the exocyst complex (2, 
6, 13, 21, 47), a process reported to be required for the transforming ability of RalA and 
RalB (27). While both RalA and RalB utilize the exocyst complex RalA seems to 
primarily utilize the exocyst for transformation whereas RalB preferentially utilizes 
components of the exocyst for exocyst-independent functions in regulating cell mobility 
(7, 39). In fact, RalA and RalB are the only known binding partners for two competitive 
regulatory elements of the exocyst; Exo84 and Sec5. Therefore, the inhibition of RalA 
and RalB by GGTI-2417 represents a novel mechanism to inhibit exocyst function in 
transformed cells.  
Beyond the exocytic and endocytic trafficking pathways RalA and RalB may 
regulate important interactions with the actin cytoskeleton through their association with 
RalBP1, Rho GTPase activating protein, and filamin, an actin-binding partner (31).  
Indeed, while many small GTPases, such as Cdc42, Rac, and Rho, bind filamin, only 
RalA and RalB bind filamin in a GTP-dependent manner. Therefore, the effects of 
GGTIs on cytoskeletal organization may be mediated by inhibition of RalA and/or RalB 
geranylgeranylation. In the course of our study we observed that RalB-F, but not RalA-F, 
inhibited GGTI-induced cell rounding in MiaPaCa2 cells concurrent with inhibition of 
actin fiber formation (data not shown). This is indicative of a disruption in the cell-cell 
junctions and the underlying actin driven membrane formations. This raises the 
provocative hypothesis that at least part of GGTI effects could be due to inhibition of 
normal cell-cell patterning. This is consistent with the fact that RalA is required for 
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 basolateral sorting and delivery of E-cadherin (45), an important component of cell 
junctions and sheet patterning. Furthermore, it has been previously reported that 
cadherins mediate growth suppression by potently inducing p27Kip1 levels in a variety of 
cell lines (46).  It is thus an intriguing possibility that aberrant activation of Ral proteins 
could mediate further aberrations in vesicle sorting of cadherins and contribute to 
suppression of p27Kip1 levels. Disruption of Ral-mediated vesicle sorting of cadherins 
by GGTIs could constitute a mechanism for the anti-neoplastic activity of GGTase I 
inhibition. Further, cadherin clustering and expression levels can regulate survivin levels 
(19).  This suggests that sorting of basolateral and apical membrane proteins, such as 
cadherins, could be a Ral-dependent pathway that is required for tumor cell proliferation 
and survival and is sensitive to perturbation by GGTIs.  
The anti-neoplastic activity of GGTIs is likely to be a consequence of inhibiting 
the function of multiple, functionally distinct GGTase I substrates. However, our 
chemical biology approach has clearly delineated non-overlapping roles for RalA and 
RalB in anchorage-independent and -dependent growth and demonstrates that inhibition 
of RalA and RalB geranylgeranylation is an important step in the mechanism of action of 
GGTIs. Specifically, we have identified three novel pathways that are associated with the 
GGTIs response: first, a RalB-dependent induction of the p27Kip1 pathway; second, a 
RalB maintenance of the survivin pathway and third, a RalA anchorage-independent 
proliferation pathway. The first two pathways are associated with the ability of GGTI to 
inhibit anchorage-dependent proliferation and survival. Further characterizing these 
pathways should prove to be an interesting and important contribution to the study of Ral 
biology. We feel these results should prompt a thorough examination of GGTI 
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 mechanism of action with particular attention focused on the Ral family in both future 
clinical trials and in preclinical models.  
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 Abstract 
 
In addition to the high prevalence of inactivating mutations of p53 and Rb tumor 
suppressors, oncogenic mutations of the Ras genes are also common in human ovarian 
cancer; however, the downstream effectors required for Ras transformation in this disease 
are not known.   Using a genetically defined human ovarian epithelial cell model in 
which stable expression of H- or K-Ras12V drives transformation of ovarian surface 
epithelial cells (T80) immortalized by SV40 Large T antigen (SV40T) and activated 
human telomerase reverse transcriptase catalytic subunit (hTERT), we have delineated a 
requirement for Ral A/B and Akt1/2 but not Raf-1 or Mek1/2 expression and activation in 
Ras transformation.. Knockdown of expression of the RalGDS effectors RalA and RalB, 
and the PI3K effectors Akt1/2, but not Raf-1 and Mek1/2 inhibited H- and K-Ras 
transformation. Furthermore, stable expression of K-Ras12V effector loop mutants 
revealed that activation of either RalGDS with Ras12V37G or PI3K withRas12V40C, but not 
Raf-1 with Ras12V35S, was sufficient to transform T80 cells. In further support of Ral and 
Akt as the primary transforming components of the H- and K-Ras signaling cascade 
perturbation of Ral or Akt but not Raf-1 signaling pathways by pharmacologic inhibitors 
attenuated Ras transformation. These results sharply contrast with previous studies which 
have reduced the requirements for Ras transformation in spontaneously immortalized rat 
ovarian surface epithelial cells to Ras/Raf signaling. 
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 Introduction 
 Ovarian cancer is the primary cause of death among gynecological malignancies 
and is the 5th leading cause of cancer deaths among women in the United States (12). 
Despite the high incidence of ovarian cancer among women and the relative lethality of 
the disease little is known about the precise mechanism of transformation of human 
ovarian surface epithelial (HOSE) cells. Indeed, multiple mechanisms of ovarian surface 
epithelial cell transformation have been proposed and are believed to be sub-type specific 
(3). The two most common sub-types of ovarian cancer, high-grade serous and mucinous 
ovarian carcinoma (12), are commonly diagnosed at late-stage and are frequently lethal 
due to a high-propensity for both metastasis and drug-resistant recurrence (3, 12). It is 
thus of critical importance to define the mechanism of ovarian epithelial cell 
transformation both for a more precise understanding of the underlying genetic risk 
factors as well as for the development of targeted therapies for treatment.  
 Epithelial neoplasias, such as ovarian cancers, exhibit multiple genetic aberrations 
in key tumor suppressor genes, so-called “cellular gatekeepers” such as p53 and Rb(16). 
Indeed, over 50% of ovarian cancers exhibit missense mutations resulting inactivation of 
p53 (25, 30). Furthermore, over 80% of human ovarian cancers examined have been 
shown to have mutational defects in one or more of the genes involved in the Rb tumor 
suppressive pathway, such as CDK4, cyclin D1, and Rb (17). Activation of human 
telomerase (hTERT) activity is another well-recognized defect of human epithelial 
neoplasms including ovarian cancer [3,7].  In addition to p53, Rb and hTERT genetic 
abnormalities, activation of one or more proto-oncogenes is a pivotal fourth event in the 
development of human epithelial malignant disease.  
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 Mutations in Ras proto-oncogene family members (H-, K-, and N- Ras) are 
known to occur in approximately 30% of human cancers (40).  Numerous studies have 
demonstrated that mutational activation of K-Ras, through missense mutations at codons 
12 and 13, occurs with high frequency (27-69%) in certain subtypes of ovarian cancers 
(7, 11, 20, 33, 44). Similar mutations in the H-Ras proto-oncogene have been determined 
to occur in ovarian cancer subtypes though there is considerable disagreement over the 
frequency (9, 44, 53).A role for Ras mutation in ovarian cancer progression is especially 
well recognized in mucinous sub-type ovarian tumors where the incidence of K-Ras 
proto-oncogene mutation increases profoundly during the progression of disease (33). For 
example, Mok and colleagues found a high, progression-dependent incidence of K-Ras 
activation at codons 12 and 13 in 13% of mucinous adenomas, 33% of mucinous tumors 
at the borderline, and 46% of mucinous carcinomas (33). Similar results have been 
reported by many other groups (7, 9, 20, 33, 44). K-Ras mutation have also been 
detected, albeit to a lesser degree (up to12% only), in high-grade serous sub-type ovarian 
cancer, the most common form of ovarian malignancy (33). It is interesting to note that a 
much higher incidence of Ras mutation exists in low-grade serous malignancy. Indeed, 
over 68% of low grade serous tumors have either a Ras or Raf mutation (31), and Ras 
muations have  been found in up to 48% of borderline ovarian epithelial tumors (33) 
indicating a role for Ras mutations in the early events of low-grade serous ovarian 
neoplasia.  
Recently, genetically defined models of human epithelial transformation have 
been developed which have enabled, for the first time, the description of oncogene 
stimulated transformation in cells of human epithelial origin (13-15, 21, 27, 29, 37). 
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 Sequential inactivation of the tumor suppressors p53 and retinoblastoma (Rb) protein by 
ectopic expression of SV40-T-antigen (TAg) or polyoma middle T antigen (PoMT), 
coupled with stable expression of human telomerase catalytic subunit (hTERT) in human 
epithelial and fibroblastic cell lines recapitulates the critical events in the development of 
human neoplastic disease and creates a minimally transformed model for the study of 
oncogenic signaling pathways (13, 14). Creation of these models has prompted a 
reexamination of the essential downstream signaling components of the Ras oncogene. 
Previous reports in the spontaneously immortalized NIH-3T3 murine fibroblast model 
identified the Raf-MEK-Erk pathway, but not phosphatidylinositol 3’ kinase (PI3K)-Akt 
or Ral guaunine nucleotide dissociation stimulator (RLGDS)-Ral pathways, as being 
necessary and sufficient to promote Ras-mediated growth and morphologic 
transformation (38). However, recent work has demonstrated tissue- and species-specific 
requirements for Ras downstream effectors, other than Raf, in malignant transformation 
(15, 27, 37).While in one study [19], the only Ras effector pathway to show independent 
transforming activity in the human embryonic kidney cell system (HEK-HT) was 
RalGEF-RalA small GTPase pathway, whereas in another study [23] both Ras/RalGEF 
and Ras/PI3K pathways were required for Ras transformation in the same HEK-HT 
model.. In contrast, in human mammary epithelial cells (HMECs), which are minimally 
transformed by hTERT and TAg, Ras transformation requires concurrent activation of 
Raf, RalGEF, and PI3K.  Yet in another study [26], spontaneously immortalized rat 
ovarian surface epithelial (ROSE) cells, Raf but not PI3K or RalGEF, was independently 
transforming.  Therefore, the requirements for Ras transformation appear to be highly 
dependent on the tissue and species of origin. 
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 For ovarian cancer, while the ROSE cell model has been useful in suggesting 
which signaling cascades are required for Ras transformation in ovarian epithelial cells, it 
is neither genetically defined nor of human origin. Thus, while suggestive of a role for 
Raf in ovarian transformation, the ROSE model has unknown prognostic significance for 
human ovarian oncogenesis. Recently, a genetically defined human model of ovarian 
malignancy has been developed which recapitulates the critical events in neoplasia (29). 
The T80 cell line is derived from primary human ovarian surface epithelial cells 
engineered to express TAg and hTERT. Upon the addition of retrovirally transduced H-
Ras12V, these cells, referred to as T80H, acquire anchorage independent growth capability 
in soft agar and are capable of forming xenograft tumors in a SCID mouse model. This 
transformation requires continued expression of H-Ras (49) and, as such, is a bona fide 
model of Ras-dependent, ovarian cell-type-specific transformation. Using this system, as 
well as our own stable K-Ras12V expressing variant (T80K), we selectively attenuated Ras 
signaling to the three primary Ras signal transduction pathways (RalGEF-Ral, PI3K-Akt, 
and Raf-MEK-Erk) using a combination of genetic and pharmacological approaches, as 
well as ectopic expression of Ras effector loop mutants to determine which of the 
downstream signaling components are required for human ovarian surface epithelial cell 
transformation. In contrast to the ROSE cell model we have determined that RalGEF-Ral 
and PI3K-Akt but not Raf-MEK-Erk are the primary pathways of Ras transformation of 
human ovarian epithelial cells. 
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 Materials and Methods 
Cells and culture—Human ovarian surface epithelial cells T80 and T80H were cultured 
as described previously (29). The T80K, T80K12V35S, T80K12V37G, T80K12V40C, stably 
expressing cell lines were maintained in similar culture conditions as the T80 and T80H 
cells [22]. Human HEK-293T was a kind gift from Dr. Gary Reuther and were 
maintained in Dulbecco’s modified minimum essential medium (DMEM) 10% fetal 
bovine serum and 1% penicillin/ streptomycin at 10% CO2 and 37ºC. 
Plasmids- Retroviral plasmids pBABE-puro containing the K-Ras12V, KRas12V35S, 
KRas12V37G and KRas12V40C transgenes were a kind gift from Dr. Gary Reuther (15). 
Creation of retrovirus- Retrovirus was created by transient transfection of HEK-293T 
human embryonic kidney cells with pVPACK-Ampho, pVPACK-gag-pol and pBABE 
retroviral plasmids as previously described (10). Briefly, 293T cells were seeded at 
2.5x106 cells in a 60mm2 dish. 3 µg of each plasmid was combined and brought to a 
volume of 225 µl in RNase/DNase free water, following which 25 µl 2.5M CaCl2 was 
added dropwise while gently vortexing. This solution was then added to 250 µl 2x 
HEPES Buffered Saline dropwise and incubated at room temperature for 5 min. The total 
volume of 500 µl was then added to the 293T cells and incubated for 8 hs at 37°C. The 
media was then removed and cells were incubated for 48 h. The supernatant was then 
passed through a 0.45 µm nylon low protein-binding filter to remove cells and cell debris.  
Creation of stable cell lines- T80 cells were seeded into 6 well plates at a 40% 
confluency and incubated with 10 µg/mL polybrene (Millipore/ Specialty Media, 
Billirika, MA) and a 1:3 dilution of retrovirus containing conditioned media for 72 h. 
Media was then replaced with complete growth medium containing 1.0 µg/mL 
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 puromycin and incubated until colonies formed. All colonies were pooled and taken as a 
single polyclonal population and cultured in complete medium.  
Small interfering RNA (siRNA)  sequences- SiRNA sequences targeting RalA and RalB 
were purchased from Dharmacon using previously described described sequences (6). 
Specifically, RalA: 5'-GACAGGUUUCUGUAGAAGAdTdT-3', RalB: 5'-
GGUGAUCAUGGUUGGCAGCdTdT-3'. Pre-designed chemically synthesized siRNA 
targeting Akt1/2 (Cat #6211, Cell Signaling Technology Inc., Danvers, MA), Raf1 (Cat 
#M-003601-00, Dharmacon, Lafayette, CO) MEK1 (Cat #6420, Cell Signaling 
Technology Inc., Danvers, MA) and MEK2 (Cat #6431, Cell Signaling Technology Inc., 
Danvers, MA) were used according to manufacturer’s recommendation. 
Small interfering RNA (siRNA) transfection procedure- Cells were grown to 50% 
confluence and transfected with Oligofectamine transfection reagent (Invitrogen, 
Carlsbad, CA) according to manufacturer’s instructions. Briefly, 5 µl of oligofectamine 
reagent was suspended per 1 mL of OPTI-MEM media (Invitrogen, Carlsbad, CA) and 
allowed to equilibrate at 24-27°C.  A 100 nM final concentration of siRNA was 
suspended and allowed to complex with the liposomes. Cells were briefly washed with 
OPTI-MEM and the transfection mix was plated on top of the cells and incubated at 
37°C. Following 8 h incubation 2 mL of complete growth media, without penicillin-
streptomycin, was added and the cells were further incubated at 37°C overnight. The 
media was replaced after 24 h with complete growth medium for 24 h. Experiments were 
performed in triplicate.  
Pharmacological inhibitors – Cells were treated for 48 h with either DMSO vehicle 
(Sigma-Aldrich, St. Louis, MO), 20 µM LY29004 (Calbiochem, San Diego, CA), 10 µM 
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 U0126 (Sigma-Aldrich, St. Louis, MO), or 10 µM GGTI-2417 (36). Experiments were 
performed in triplicate.  
Western blotting—Cells were harvested, and lysed in HEPES lysis buffer as described 
previously (10). Proteins were then resolved by 11.5% SDS-PAGE gel and 
immunoblotted with antibodies against phosphorylated-Ser473 Akt1/2 (9217, Cell 
Signaling Technologies Inc., Danvers, MA), phosphorylated-Thr202/Tyr 204 Erk1/2 
(9101, Cell Signaling Technologies Inc., Danvers, MA), Akt1/2 (N-19, Santa Cruz 
Biotechnology, Santa Cruz, CA), Erk1/2 (p44/p42 MAP Kinase, 9102, Cell Signaling 
Technologies Inc., Danvers, MA), RalA (61022, BD Biosciences Pharmingen, Franklin 
Lakes, NJ), H-Ras(C-20, Santa Cruz Biotechnology, Santa Cruz, CA), K-Ras (F234, 
Santa Cruz Biotechnology, Santa Cruz, CA), RalB (04037, Millipore, Billerika, MA), β-
actin (AC15, Sigma-Aldrich, St. Louis, MO) and anti-FLAG M2 monoclonal antibody 
(Sigma-Aldrich, St. Louis, MO). The ECL blotting system (NEN Life Science Products, 
Boston, MA) was used for detection of positive antibody reactions. Experiments were 
performed in triplicate.  
Soft agar clonogenicity assay- For soft agar growth assays, the cell lines were seeded at a 
cell density of 5000/well in triplicate in 12-well culture dishes in 0.3% agar over a 0.6% 
bottom agar layer as previously described (10). Cultures were fed once weekly until 
colonies grew to a suitable size for observation (approximately 14 days). Colonies were 
photographed after overnight incubation with 1 mg/ml MTT in cell growth media. 
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 Colony number was visually determined and quantified. Experiments were performed in 
triplicate and 3 independent experiments were performed.  
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 Results 
Differential transforming activity and signaling activation by H- and K- Ras12V 
isoforms in the T80 human ovarian surface epithelial (HOSE) cell line.  
 The incidence of K-Ras mutation in ovarian malignancy is far greater than that of 
H-Ras (3, 7, 9, 20), suggesting a preferential role for K-Ras in the development of 
ovarian neoplasia. Additionally, while Ras isoforms are commonly assumed to activate 
the same three primary transformative pathways; Raf/MEK/Erk, PI3K/Akt and RalGDS/ 
Ral, the degree to which H- and K- Ras isoforms activate these pathways vary according 
to both physical association constants (8, 48) as well as cell-type specific differences (15, 
26, 37, 43). Therefore, we first wanted to examine differences in both the transformative 
capability and the signaling pathway utilization of oncogenic, mutated H- and K- 
Ras12Vin the HOSE T80 cell model where hTERT is overexpressed and p53 and Rb are 
inactivated by Tag as described in Liu et al (29).To this end, we created a T80 cell line 
stably expressing oncogenic K-Ras12V (T80-K) as described under Materials and 
Methods. The T80 cell line stably expressing oncogenic H-Ras12V (T80H) was obtained 
from Dr. Bast (29). We first compared the downstream effector utilization of the two Ras 
isoforms by SDS-PAGE and western blot analysis as well as Ral-GTP binding assay 
(figures 12A and 12B, see following pages). Both H- and K-Ras12V potently stimulated 
GTP loading of RalA and RalB to a similar extent. However, while both H-Ras12V and K-
Ras12V induced phosphorylation of Akt1/2 and Erk1/2, K-Ras12V was relatively less 
potent; indicating a differential specificity of the Ras isoforms for activation of Akt and 
Erk in the human ovarian cancer cell model.   Finally, we used anchorage-independent 
growth on soft agar to show that ectopic expression of both mutant H-Ras12V and K-
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 Ras12V promotes soft agar clonogenicity in the T-80 model.  Figure 12C shows that 
whereas T80 grew only 42 ± 5colonies, T80-H and T80-K grew 183 ± 28 (p<0.05) and 
114 ± 13 (p<0.01) colonies, respectively. 
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Figure 12. Differential transforming activity and signaling 
activation by H- and K- Ras12V in human ovarian surface epithelial 
(HOSE) cells
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Figure 12. Differential transforming activity and signaling activation by 
H- and K- Ras12V in human ovarian surface epithelial (HOSE) cells
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Figure 12. Differential transforming activity and signaling activation by 
H- and K- Ras12V isoforms in the T80 human ovarian surface epithelial 
(HOSE) cell line. T80 cells stably transduced with H- Ras12V (T80H) or K-
Ras12V (T80K) were collected and lysed. Proteins were separated by SDS-
PAGE and used for Ral-GTP quantitation using GST-RalBP pull down 
assay (A) or western blot analysis (B); results are representative of three 
experiments. T80, T80H and T80K cells were seeded into 0.3% soft agar for 
two weeks, colonies were manually scored (C); T80 cells formed 43+/-5 
colonies per well, T80H formed 183+/-28 colonies per well and T80K 
formed 114+/-13 colonies per well. Results are representative of three 
experiments each performed in triplicate. 
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 Ras transformation of human ovarian surface epithelial cells requires expression of 
RalA/B and Akt1/2 but not Raf1 or Mek1/2. 
 We next determined the requirements for expression of the Ras effectors 
RalA, RalB, Akt1/2, and Raf1 and Mek1/2 in both H- and K- Ras12V mediated 
transformation of T80 cells. For these analyses, we used siRNA to RalA, RalB, Akt1/2 
and Raf1 and Mek1/2 to specifically deplete each gene product and systematically 
evaluate the effects of this knockdown on Ras transforming capability as described under 
Materials and Methods.  Figure 13A (see following pages) shows that in both T80H and 
T80K RalA siRNA knocked down RalA, but not RalB, expression whereas RalB siRNA 
knocked down RalB, but not RalA, expression; these results demonstrated, by western 
blot analysis, that each siRNA was specific.   Figure 13B (see following pages) shows 
that knockdown of expression of RalA potently inhibited H-Ras12V and K-Ras12V 
transformation of T80 cells by 56%±7% and 54%±5%, respectively (all p values were 
less than 0.01). Similarly, knockdown of expression of RalB potently inhibited H-Ras12V 
and K-Ras12V transformation of T80 cells by 54%±11% and 66%±3%, respectively (all p 
values were less than 0.01).   Knockdown of Akt1/2 expression in both T80H and T80K 
cells (Figure 14A, see following pages) inhibited transformation by 46%±3% and 
42%±5%, respectively (Figure 14C, all p values were less than 0.05).  In contrast 
knockdown of Raf1 expression (Figure 3A, see following pages) did not have any 
statistically significant effect on the clonogenicity of T80K and T80H cells (Figure 14C, 
see following pages). Since inhibition of Raf1 expression did not result in reduction of 
Ras transformation we aimed to further evaluate the role of Raf/MEK/Erk signaling by 
knocking down the expression of Mek1/2.   While inhibition of Mek1/2 expression 
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 resulted in the attenuation of Erk1/2 phosphorylation (figure 14B, see following pages), it 
did not inhibit either H-Ras12V or K-Ras12V transformation (figure 14C, see following 
pages). These results suggest that RalA, RalB and Akt1/2, but not Raf1 or Mek1/2, are 
essential components of Ras mediated human ovarian epithelial cell transformation.  
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Figure 13. Ras transformation of HOSE cells requires expression of 
RalA/B.
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Figure 13. Ras transformation of HOSE cells requires expression of RalA and RalB. 
Small interfering RNA (siRNA) specific to RalA and RalB or a negative control siRNA 
were transfected for 48 hours into T80, T80H and T80K cells. Cells were collected, 
counted using trypan blue dye exclusion assay and collected for western blot analysis 
(A) and an equal number of cells were plated for soft agar assay (B) and scored 
manually at the end of two weeks; for T80-H N.C. cells 153+/-11 cells = 100%, for T80-
K N.C. cells 115+/-17 cells = 100%; results are representative of three experiments each 
performed in triplicate. 
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Figure 14. Ras transformation of HOSE cells requires expression of 
Akt1/2 but not Raf1 or MEK1/2.
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Figure 14. Ras transformation of HOSE cells requires expression of 
Akt1/2 but not Raf1 or MEK1/2.
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Figure 14. Ras transformation of HOSE cells requires expression of 
Akt1/2 but not Raf1 or MEK1/2. Small interfering RNA (siRNA) 
specific to Akt1/2 and Raf1 or a negative control siRNA were transfected 
for 48 hours into T80, T80H and T80K cells. Cells were collected, counted 
using trypan blue dye exclusion assay and collected for western blot 
analysis (A) and an equal number of cells were plated for soft agar assay 
(B) and scored manually at the end of two weeks; for T80-H N.C. cells 
153+/-11 cells = 100%, for T80-K N.C. cells 115+/-17 cells = 100%; 
results are representative of three experiments each performed in triplicate. 
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 K-Ras effector loop mutants which preferentially activate RalGDS and/or PI3K, but 
not Raf1, are capable of transforming T80 HOSE cells to a similar, or greater, 
extent as compared to fully active K-Ras12V.  
To further evaluate the contributions of the Ras effector pathways RalGDS/Ral, 
PI3K/Akt, and Raf/MEK/Erk to Ras transformation in human ovarian surface epithelial 
cells we used retroviruses to stably tranduce oncogenically active K-Ras12V with effector 
loop amino acid substitutions (35S, 37G, and 40C) which are well characterized to 
restrict the interaction of Ras to, respectively, Raf-1, RalGDSand PI3K (22, 23, 32, 39, 
45, 46). Figures 15A and 15B (see following pages) show that K-Ras12V stimulated 
phosphorylation of P-Erk1/2 and Akt as well as induced RalA and Ral GTP loading. K-
Ras12V35S (which activates Raf but not PI3K or RalGDS) activated Erk1/2 
phosphorylation but did not stimulate RalA or RalB GTP loading and did not activate 
Akt1/2 phosphorylation (figure 15A and 15B, see following pages). Similarly, K-
Ras12V37G (which binds RalGDS but is defective in binding to Raf and PI3K) stimulated 
GTP-loading of RalA and RalB but did not stimulate phosphorylation of Akt1/2 and 
Erk1/2 (figure 15A and 15B, see following pages). K-Ras12V40C (which activates PI3K 
but not RalGDS or Raf) activated Akt but not Erk1/2 phosphorylation and did not 
stimulate GTP-loading of RalA or RalB (figure 15A and 15B, see following pages). 
Further evaluation of the transforming potential of these mutational variants relative to 
fully oncogenic K-Ras revealed that Ras effector loop mutants which preferentially 
activated RalGDS/Ral (K-Ras12V37G) and PI3K/Akt (K-Ras12V40C), but not Raf/MEK/Erk 
(K-Ras12V35S), were capable of transforming T80 HOSE cells to a similar or greater 
extent than K-Ras12V (figure 3C, see following pages).  For example, KRas12V and K-
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 Ras12V40C increased the number of colonies from 62 ± 16 in pBABE (T80 cells) to 195 ± 
25 and 201 ± 13 respectively.  K-Ras12V37G was more potent and resulted in 282 ± 20 
colonies.  In contrast, K-Ras12V35S was dramatically reduced in transforming potential, 
50% of K-Ras12V or 95.3±10 colonies (p value <0.005). These findings both confirmed 
and extended our results by further demonstrating the central importance of PI3K/Akt 
and RalGDS/Ral, but not Raf-1, in ovarian epithelial cell transformation. 
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Figure 15. K-Ras mutants which preferentially activate RalGDS 
and/or PI3K, but not Raf1, are capable of transforming T80 
HOSE cells to a similar, or greater, extent as compared to fully
active K-Ras12V. T80 cells stably transduced with empty vector, K-
Ras12V (T80K), K-Ras12V35S (T80K35S), K-Ras12V37G (T80K37G) or 
K-Ras12V40C (T80K40C) were collected and lysed. Cell lysates were 
separated by SDS-PAGE and used for western blot analysis (A) or 
quantitation of Ral-GTP levels using GST-RalBP pull down assay 
(B); results are representative of three experiments. T80, T80K and 
T80K35S, T80K37G and T80K40C cells were seeded into soft agar 
for two weeks, colonies were manually scored (C); results are 
representative of three experiments each performed in triplicate.
**=p<0.01 (greater than T80K), xx=p<.01(less than T80K)
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 Pharmacological inhibitors of PI3K or Ral, but not MEK, inhibit Ras 
transformation of HOSE cells. 
While we have demonstrated that expression and activation of RalGDS/Ral and 
PI3K/Akt, but not Raf-1/ Mek1/2 are required for Ras transformation we also wanted to 
determine the effects that pharmacological perturbation of these pathways would have on 
Ras transformation. We used well-characterized inhibitors of MEK (U0126) and PI3K 
(LY294006) to selectively attenuate these pathways. We also used GGTI-2417, a small 
molecule competitive inhibitor of geranylgeranyltransferase-I (36), to inhibit the 
prenylation of RalA and RalB. Both RalA and RalB require geranylgeranylation for both 
localization and biological activity (19) and are necessary components of GGTI anti-
neoplastic activities (10). As expected, pharmacological inhibition of PI3K by LY294006 
attenuated phosphorylation of Akt (Figure 16A, see following pages). LY294006 also 
inhibited P-Erk1/2 in both cell lines.  GGTI-2417, similar to our previous reports, 
inhibited the prenylation of both RalA and RalB (see slight mobility shift in Figure 16A, 
see following pages). The MEK1/2 inhibitor UO1266 partially inhibited Erk1/2 
phosphorylation, without any effect on Akt phosphorylation (Figure 16A, see following 
pages). GGTI-2417 inhibited soft agar clonogenicity by 85.5% (T80K, p value <0.005) 
and by 54.5% (T80H, p value <0.05) (Figure 16B, see following pages). LY294006 
inhibited soft agar clonogenicity by 89.6% (T80H, p value <0.01) and by 90.1% (T80K, p 
value <0.01). In contrast, UO126 did not attenuate either T80H or T80K soft agar 
clonogenicity.  
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Figure 16. Pharmacological inhibitors of PI3K or Ral, but not MEK, 
inhbit Ras transformation of HOSE cells. T80, T80H and T80K cells 
were exposed to full growth media containing either 0.01% DMSO, 
20µM LY29004, 10µM U0126, or 10µM GGTI-2417 for 48-hours. Cells 
were then collected, counted using trypan blue dye exclusion assay and 
collected for western blot analysis (A) and an equal number of cells 
were plated for soft agar assay (B) and scored manually at the end of 
two weeks; results are representative of three experiments each 
performed in triplicate. 
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 Discussion 
  Several studies (7, 11, 20, 41, 44) have implicated mutant K-Ras in the 
development of ovarian cancer, especially in mucinous sub-type malignancies, the second 
most common form of ovarian neoplasia (7, 33, 44). In this study we examined the roles 
of the three most thoroughly characterized Ras effector pathways RalGEF-Ral, PI3K-Akt 
and Raf-MEK-Erk in mediating Ras anchorage independent growth of a genetically 
defined model of human ovarian cancer. We determined that Ras anchorage independent 
growth in this tissue type proceeds primarily through the RalGEF-Ral and PI3K-Akt 
pathways but not through Raf-MEK-Erk, in sharp contrast to previous reports that 
spontaneously immortalized rat ovarian surface epithelial cells could be transformed by 
H-Ras12V in a Raf1-dependent manner (43). It is important to note that anchorage 
independent growth is only one measure of transformation and other aspects of 
transformation, such as invasion and metastasis may require Raf1 signal transduction.  
We first determined that the transforming activity of both H- and K-Ras12V 
required the expression and activity of RalA, RalB and Akt1/2 but nor Raf1 or Mek1/2. 
We next determined that K-Ras mutants which preferentially activated RalGEF, or PI3K, 
but not Raf, were capable of transformation to a similar or greater extent than K-Ras 
capable of activating all three pathways. Importantly, we discerned that K-Ras capable of 
only activating the Raf-MEK-Erk pathway was incapable of transforming T80 cells. 
These results suggest that RalGEF or PI3K activation alone is sufficient to promote Ras-
mediated anchorage-independent growth. However, it should be emphasized that these 
effector mutants do retain the ability to bind other Ras effectors that may regulate 
transformation. For example the 37G mutant retains the ability to activate phospholipase 
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 C epsilon. We have also used pharmacological probes to provide further support for the 
role of Ral and Akt but not Raf pathways in Ras – mediated ovarian cell transformation.  
One of our initial observations was that differences exist in both transforming 
potency and effector utilization among Ras isoforms. Indeed, K-Ras12V was less potent 
than H-Ras12V in the ability to both transform and activate Akt and Erk. Interestingly, 
another independently derived T80K cell line has also exhibited similarly diminished 
transformative capability in soft agar assays (29), making it unlikely that this is an artifact 
of viral transduction. It is interesting to speculate on the causes of this differential activity 
as these results stand in marked contrast to previous studies of H-Ras12V in rat ovarian 
surface epithelial (ROSE) cells in which stable expression of H-Ras12V did not stimulate 
Akt activation in ROSE cells (43). However, we find that H-Ras12V potently stimulates 
Akt activation whereas K-Ras12V was less potent. Similarly, while stable expression of 
either Ras oncogene stimulated Erk hyper-phosphorylation, K-Ras12V was less potent. 
However, H- Ras12V and K- Ras12V were equipotent in their ability to stimulate GTP-
loading of RalA and RalB. While these results suggest a species-specific difference in 
Ras isoform effector utilization, at least when compared to the previous studies in ROSE 
cells (43), there has been no effort to systematically determine Ras isoform tissue-
specific differences in effector utilization. However, previous studies in murine fibroblast 
NIH-3T3 cells indicate that H-Ras preferentially activates Erk whereas K-Ras 
preferentially activates Akt (48). We next determined which limbs of the Ras pathways 
are required for its ability to transform HOSE cells.   
We found that either specific depletion of RalA or RalB by siRNA or inhibition of 
Ral prenylation by GGTI-2417 was sufficient to strongly attenuate transformation by 
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 Ras12V. Others have previously demonstrated a central requirement for RalGDS (27), and 
specifically RalA, in the transformative activity of H-Ras12V in HEK-HT cells. 
Furthermore, studies in NIH-3T3 fibroblasts have shown that ectopic expression of 
dominant negative RalA can partially reverse Ras-dependent transformation (1);  and 
inhibition of RalA by either siRNA mediated depletion or overexpression of dominant 
negative RalA has been shown to inhibit anchorage independent proliferation, invasion 
and metastasis of human tumor cell lines of non-ovarian origin (6, 45, 51). While RalB 
expression was previously described as dispensable for H-Ras12V mediated 
transformation of human embryonic epithelial kidney cells (27) we have found a central 
requirement for RalB in both H- and K-Ras12V transformation of ovarian epithelial cells. 
Indeed, the effects of depletion of RalB by siRNA were equivalent to depletion of RalA 
in attenuating clonogenicity of T80H and T80K cells.  However, we have also previously 
reported in the human pancreatic cancer cell line MiaPaCa2 biological differences 
between RalA and RalB, which suggested a role for RalA but not RalB in clonogenicity 
(10). Using a chemical biology approach we determined that GGTI-insensitive mutants of 
RalA rescued from GGTI-inhibition of anchorage-independent growth while similar 
mutants of RalB rescued from divergent processes such as inhibition of anchorage-
dependent proliferation, induction of apoptosis, increase in p27Kip1 and decrease in 
survivin in human pancreatic cancer cells (10).  Others, such as White, Theoderescu, Der 
and Counter have used siRNA to RalA and RalB to similarly demonstrate divergence 
between the Ral isoforms in multiple human pancreatic and renal cancer cell lines, as 
well as certain human cervical and prostate cancer cell lines, respectively HeLa and 
SW480 (6, 28, 35). Given the presumed biologically divergent roles of the Ral family it is 
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 interesting to consider whether the ability of RalA and RalB expression to govern Ras 
transformation is through redundant or divergent pathways. 
In support of a role for RalGEF/Ral signaling in the progression of ovarian 
cancer, expression of K-Ras12V37G, which is deficient for activation of Raf-1 and PI3K, 
activated GTP-loading of RalA and RalB to a similar extent as K-Ras12V and was able to 
transform to a similar or greater extent than K-Ras12V in T80 cells. This is similar to the 
results in the HEK-HT system reported by the Counter lab in which H-Ras12V37G had 
independent transformative capability (27) but stands in marked contrast to the results of 
the Weinberg lab where H-Ras12V37G was only transforming when combined with 
activation of PI3K (15).   
We have also identified the PI3K/Akt pathway as being central for Ras-induced 
ovarian oncogenesis. Indeed, previous studies on the PI3K/Akt signaling pathway in 
ovarian cancer provide ample evidence that aberrations in this pathway could play an 
important role in the progression of ovarian neoplasia. Specifically, Akt2 kinase activity 
is elevated in ovarian carcinoma patient biopsies (52), Akt2 gene amplification occurs in 
12-18% of ovarian carcinoma samples analyzed (2, 5) and mutation of PI3K p110 subunit 
occurs in 20% of serous carcinomas (47). However, none of these observations have been 
correlated to Ras mutational status. Our results demonstrate that inhibition of Akt1/2 
expression by siRNA and inhibition of Akt activation by the PI3K inhibitor LY294006 
strongly attenuated both T80H and T80K transformation. These results are in 
concurrence with previous reports in ROSE cells in which LY294006, an inhibitor of 
PI3K, reversed H-Ras12V transformation (43). However, in this system since H-Ras12V 
expression did not result in hyperphosphorylation of Akt1, or Akt2, no role could be 
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 assigned to Akt signaling. In contrast in our present study we found both H-Ras12V and 
K-Ras12V could activate Akt1/2. This is consistent with previous studies in spontaneously 
immortalized NIH-3T3 murine fibroblasts and rat intestinal epithelial (RIE) cells that 
have correlated Ras isoform transformation potential to the activation of PI3K (26).  
However, it is important to note, despite the lower level of Akt activation by K-Ras12V as 
opposed to H-Ras12V both T80H and T80K cell lines were equally sensitive to inhibition 
of Akt activation by LY and expression knockdown by Akt siRNA. Ascribing a causal 
role for PI3K and Akt in Ras transformation of epithelial cells is particularly important 
given the wealth of small molecules currently under clinical investigation as anti-
neoplastic agents which target PI3K and Akt (18). Indeed, one of these compounds, 
triciribine monophosphate (TCNP) (50), is currently in phase I trials in patients where 
tumors (including ovarian) contain persistently activated hyper-phosphorylated Akt 
(Clinical trial #NCT00363454). Our results suggest inhibition of either PI3K or Akt 
could be beneficial to patients harboring Ras mutation positive ovarian tumors.    
In further support of a role for PI3K/Akt signaling in the ovarian neoplastic 
processes independent of Ras we have found KRas12V40C, activates Akt to a similar extent 
as K-Ras12V and is capable of similar transforming activity. However, since this effector 
domain mutant retains the ability to bind to other Ras effectors, more definitive 
demonstration of this will require a more thorough examination of the independent 
transforming activity of constitutively activated Akt and PI3K isoforms. Previous cell 
line systems, such as HEK-HT and HMEC have not ascribed an independent role for 
PI3K/Akt signaling in the induction of epithelial oncogenesis however PI3K-Akt 
signaling was required for maintenance of Ras transformation in HEK-HT cells (6, 15). 
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 Furthermore, given both frequency of PTEN deletions in ovarian cancer (24) and the 
presence of activating point mutations in PI3K p110 gene (47) as well as Akt1 and Akt2 
(4, 34, 42) these results are consistent with epidemiologic observations.  To date most 
studies carried out have examined the overlapping incidence of BRAF and RAS 
mutations. While some limited studies have focused on understanding the overlapping 
frequency of RAS and PI3K mutations in ovarian cancer , these results suggest further 
analysis of the mutational status of the various Ras effectors, such as mutational 
aberrations in PI3K/Akt signaling and the various RalGEFS, relative to Ras mutation 
among the various sub-types of ovarian cancer is warranted.  
Perhaps most interestingly our results suggest that Raf/Mek/Erk stimulation does 
not play a substantial role in either H- or K-Ras12V transformation of human ovarian 
surface epithelial cells. Stable expression of K-Ras12V35S, deficient for activation of PI3K 
and RalGDS, activated Erk phosphorylation to a similar extent as K-Ras12V but lacked 
transformative capacity in T80 cells. Furthermore, specific depletion of either Raf1 or 
MEK1/2 by siRNA or pharmacologic inhibition of MEK by U0126 did not affect Ras 
mediated transformation. Taken together, these results suggest that ovarian cancer 
patients with ovarian subtypes typically devoid of BRAF mutations, and whose tumors 
harbor activating Ras mutations, might not benefit from Raf or MEK inhibitors currently 
in clinical use.  
In summary we have described, for the first time, the essential pathways for Ras 
transformation in human ovarian surface epithelial cells. We have reduced these signaling 
requirements to activation of RalA, RalB and Akt1/2 and have further demonstrated that 
specific inhibition of these proteins by either small interfering RNA or by pharmacologic 
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 inhibition is potently limiting to Ras transformation of an experimentally derived ovarian 
model. These results validate the Ral-GDS/Ral and the PI3K/Akt pathways as targets for 
developing novel anti-cancer drugs to combat ovarian cancer.  To this end, we have 
recently identified a selective Akt activation inhibitor, triciribine monophosphate or API-
002, which will soon enter phase II clinical trials (50).  Similarly, our GGTase I inhibitor, 
GGTI-2418, is undergoing advanced preclinical studies and will soon enter phase I 
clinical trials.  Finally, while we have isolated the Ras signal transduction pathways 
required for ovarian transformation whether actiavted RalGEFs and/or PI3K isoformes 
can independently transform ovarian surface epithelial cells remains unknown and could 
further define the central requirements for human surface ovarian epithelial cell 
oncogenesis.  
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Abstract  
 
RalA and B proteins mediate Ras malignant transformation in multiple human 
epithelial cell types and have been determined to be independently transforming in a 
tissue specific manner. However, very little is known about the protein-binding partners 
that govern Ral A and B biological activities. Here, we have used a proteomics approach 
to describe a proposed database of novel Ral interacting proteins. Despite a greater than 
85% sequence similarity RalA and RalB interact primarily with different proteins. 
However, the proposed database also contains common interacting partners.  For 
example, we have identified and validated RACK1/GBLP as a novel RalA and RalB 
interacting protein. Specifically, we have determined that RACK1 interacts with 
ectopically expressed RalA and RalB as well as with endogenous RalA. Furthermore, 
depletion of RACK1 by siRNA phenocopies the effects of RalA and RalB depletion in 
reducing the ability of oncogenic H-Ras12V and K- Ras12V to transform human ovarian 
epithelial  cells.  These results both expand the number of proposed Ral A and B protein 
binding partners. They also led us to identify a specific protein interaction with RACK1 
and identify RACK1 expression as a central requirement for both H-Ras12V and K- Ras12V 
transformation of human ovarian surface epithelial cells.  
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Introduction 
 
One of the best studied mechanisms of oncogenesis in human cancer is mutational 
activation of members of the Ras GTPase gene family. Mutations in Ras gene family 
members (H-, K-, and N- Ras) occur in approximately 30% of human cancers (6). 
Mutation of Ras isoforms has been associated with progression of numerous types of 
human epithelial cancer such as pancreatic, lung, ovarian and breast (6, 16, 19). Recently, 
we (Falsetti and Sebti manuscript in submission) and others (18, 37) have used 
genetically defined models of human epithelial transformation to describe the tissue 
specific mechanisms of Ras transformation (18, 37). In these models, sequential 
inactivation of the tumor suppressors p53 and retinoblastoma (Rb) protein by ectopic 
expression of SV40-T-antigen (SV40-T), coupled with stable expression of human 
telomerase catalytic subunit (hTERT) in human epithelial cells recapitulates the critical 
events in the development of human neoplastic disease and creates a minimally 
transformed model for the study of oncogenic signaling pathways (15-17, 19). Addition 
of constitutively activated H- or K- Ras12V results in a robust transformation response and 
mimics many of the pathological events of tumor progression (15-17, 19, 28). Multiple 
studies have used a combination of pharmacological and genetic approaches to determine 
the tissue specific requirements for Ras transformation. Interestingly, all of these studies 
indicate that the Ras/ Ral guanine nucleotide dissociation stimulator (RalGDS)/Ral 
signaling pathway is required for human epithelial cell transformation by oncogenic Ras. 
Both Counter and Weinberg’s groups have separately reported that in sequentially 
transformed human embryonic kidney (HEK-HT) cells RalGDS/Ral signaling is required 
for Ras transformation (18, 37). Counter’s group has specifically defined a RalGDS/RalA 
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signaling axis which is independently transforming in this system while Weinberg’s 
group has determined that Ras requires both RalGDS and phosphotidyl-inositol 3,4,5-
triphosphate (PI3K) signaling for transformation in a similar, independently derived, 
human embryonic kidney cell line. These proposed mechanisms of Ras transformation 
are not common to all human epithelial cell lines; for example, in a genetically defined 
model of human mammary tumorigenesis, the human mammary epithelial cell line 
(HMEC), Ras transformation requires activation of at least three downstream effector 
pathways: RalGEF-Ral, PI3K-Akt and Raf-Mek (37). We have previously used a 
genetically defined model of human ovarian cancer, human ovarian surface epithelial 
cells (T80), to determine that H- and K-Ras12V transformation of human ovarian cells 
requires RalGEF-Ral and PI3K-Akt, but not Raf-Mek, signaling. In further 
confirmation of a role for the Ral small GTPases in oncogenesis both RalA and RalB 
have been identified as critical mediators of multiple tumorigenic processes, including 
metastasis, invasion, anchorage-independent growth, survival and cell motility (8, 11, 34, 
42, 43, 46).  Specifically, depletion of RalA by siRNA has been shown to inhibit 
anchorage-independent proliferation of multiple human cancer cell lines, such as the 
cervical and prostate cancer cell lines HeLa and SW680 (8) as well as multiple human 
pancreatic cancer cell lines (27). Also, RalA has also been shown to be required for 
anchorage independent growth of sequentially Ras transformed human ovarian (Falsetti 
and Sebti, manuscript in submission) and kidney cells (26). Similarly, stable depletion of 
RalA, but not RalB, by shRNA has been shown to inhibit tumor formation and metastasis 
of multiple human pancreatic cancer cell lines in athymic nude mice (27). Further 
confirming a role for RalA in metastasis, stable overexpression of constitutively activated 
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RalA has been shown to promote both standard and experimental metastasis in vivo (41, 
42) and in human prostate cancer cells stable expression of activated RalA promotes 
bone, but not brain, metastasis (47). Even in non-epithelial cancers there is emerging 
evidence that RalA is involved in tumorigenicity; for example, in human HT1080 
fibrosarcoma cells stable overexpression of activated RalA promotes anchorage-
independent growth (46). In agreement with these findings two cellular processes thought 
to promote metastasis and anchorage independent growth, cell motility and invasion, are 
inhibited by siRNA mediated depletion of RalA in multiple human renal cancer cell lines 
(34).   
 While RalA has been well validated to play an essential role in anchorage 
independent processes in multiple tissue types the role of RalB has been determined to be 
far more tissue specific. For example, while depletion of either RalA or RalB inhibits 
anchorage independent growth in human ovarian epithelial cells transformed by either H- 
or K-Ras12V (Falsetti et al, manuscript in submission) only depletion of RalA but not 
RalB inhibits H-Ras12V transformation of HEK-HT cells (26). We, as well as others have 
previously determined a role for RalB, but not RalA in the survival of multiple human 
cancer cell lines (8, 11). Specifically, White’s group has found that depletion of RalB by 
siRNA induces apoptosis in both HeLa and SW680 human cancer cell lines (8). 
Similarly, we have previously determined using a chemical biology approach that a RalB, 
but not RalA, survival pathway underlies the apoptotic response to 
geranylgeranyltransferase I inhibitors (GGTIs) (11). Specifically, by ectopically 
expressing a GGTI-resistant RalB mutant in human pancreatic carcinoma cells 
(MiaPaCa2) we have shown that GGTI-induction of apoptosis requires inhibition of 
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RalB, but not RalA, processing (11). Taken as a whole, these studies strongly suggest a 
role for RalB tumor survival in a wide array of tissue types as well as a tissue specific 
role in anchorage independent growth.  
 Despite the wealth of information regarding the role of Ral small GTPases in 
transformation very little is known about the pathways through which Ral exerts these 
effects. For example, while RalA and RalB bear a high similarity to Ras over 20 Ras 
effectors  (6, 39),but  only 6 Ral effectors have been described to date. RalA and/or RalB 
have been previously shown to interact with phospholipase D1 (PLD1), the exocyst 
components Sec5/ Exo84, Filamin A, ZO-1 N-terminally associated binding protein 
(ZONAB) and Ral binding protein-1 (RalBP1/RLIP) (12). Precise roles for these proteins 
in the various transformation specific processes that are regulated by RalA and RalB 
remain poorly defined. Further underscoring the need for an understanding of Ral protein 
interactions,  while RalA and RalB are commonly thought of as Ras effector proteins 
both RalA and RalB are found in the hyperactivated state independently of Ras in human 
pancreatic tumors (26, 27). Thus novel means of Ral activation and inactivation may 
constitute an important and undescribed mechanism of transformation. However, no Ral 
GTPase activating proteins (RalGAPs), which would negatively regulate RalA and RalB, 
have been described to date. Also, RalA and RalB are known to regulate diverse 
physiological processes such as signaling via STAT3, NF-ΚB, JNK and AFX (12). 
However, the intermediate proteins in these signal transduction pathways through which 
RalA and RalB exert these functions remain unknown.  
 In an effort to more fully understand the protein interactions that govern the 
biological activities of RalA and RalB we have used proteomic analysis to describe a 
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proposed database of Ral interacting proteins. We have uncovered several potential RalA 
and RalB interacting partners and used a systems biology approach to analyze the themes 
that emerge from this proposed database. We have further characterized one of these 
proteins, receptor for activated C-kinase-1 (RACK1, also known as Guanine nucleotide 
binding protein-1 [GBLP1]), as a novel RalA and RalB interacting protein that is required 
for both oncogenic H- and K- Ras mediated transformation of human ovarian surface 
epithelial (T80) cells. In addition to uncovering a critical role for RACK1 expression in 
both H- and K-Ras mediated transformation this study also constitutes the first large-
scale analysis aimed at uncovering the biological differences and similarities between the 
Ral isoforms and provides an important database of potential proteins through which 
RalA and RalB may mediate their biological functions.  
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Materials and Methods 
 
 Cells and culture—Human ovarian surface epithelial cells T80 and T80H were cultured 
as described previously (28). The T80Kstably expressing cell lines were maintained in 
similar culture conditions as the T80 and T80H cells. Human HEK-293T cells were a 
kind gift from Dr. Gary Reuther and were maintained in Dulbecco’s modified minimum 
essential media (DMEM) supplemented with 10% fetal bovine serum and 1% penicillin/ 
streptomycin at 10% CO2 and 37ºC.  
Immunoprecipitation of FLAG-tagged protein – FLAG-Ral proteins were isolated using 
FLAG-agarose beads according to the manufacturer’s recommendations (Sigma-Aldrich, 
St. Louis, MO). Briefly, transfected cells were lysed using Cell Lytic-M lysis byffer 
(Sigma-Aldrich) containing protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO) 
and lysates were incubated overnight with FLAG-agarose beads at 4ºC while rocking; 
after incubation the beads were washed four times with an excess of lysis buffer. 
Subsequently, samples were boiled at 100ºC for 10 minutes in 2X Laemmli sample buffer 
to elute bound proteins.  
Immunoprecipitation of RalA protein – Endogenous RalA was isolated using anti-human 
RalA mouse monoclonal antibody RalA (61022, BD Biosciences Pharmingen, Franklin 
Lakes, NJ). Briefly, T80, T80H or T80K cells were lysed using Cell Lytic-M lysis byffer 
(Sigma-Aldrich, St. Louis, MO) containing protease inhibitor cocktail (Sigma-Aldrich, 
St. Louis, MO) and lysates were incubated overnight with anti-RalA antibody at 4ºC 
while rocking; after incubation protein A anti-IgG agarose beads were added and 
incubated for 2 hours at 4ºC then washed four times with an excess of lysis buffer. 
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Following this, samples were boiled at 100ºC for 10 minutes in 2X Laemmli sample 
buffer to elute RalA and RalA binding proteins. 
Identification of Ral- interacting proteins – Following immunoprecipitation and SDS-
PAGE, gel bands were visualized using GelCode Blue (Promega, Madison, WI), excised 
and washed once with water and twice with 50 mM ammonium bicarbonate in 50% 
aqueous methanol.  Samples were digested overnight with modified sequencing grade 
trypsin (Promega, Madison, WI).  Peptides were extracted from the gel slices and 
concentrated under vacuum centrifugation.  A nanoflow liquid chromatograph (LC 
Packings/Dionex, Sunnyvale, CA) coupled to an electrospray ion trap mass spectrometer 
(LTQ Orbitrap, Thermo, San Jose, CA) was used for tandem mass spectrometry peptide 
sequencing experiments.  Peptides were separated with a C18 reverse phase column (LC 
Packings C18Pepmap, 75 um ID x 15 cm) using a 40 minute gradient from 5% B to 50% 
B (A: 2% acetonitrile/0.1% formic acid; B: 90% acetonitrile/0.1% formic acid).  Five 
tandem mass spectra were acquired for each MS1 scan (spray voltage 2.5 kV, 30% 
normalized collision energy, scanning m/z 450-1,600).  Sequences were assigned using 
Sequest (Thermo) and Mascot (www.matrixscience.com) database searches against NCBI 
or SwissProt protein entries of the appropriate species.  Oxidized methionine, 
deamidation, and carbamidomethyl cysteine were selected as variable modifications, and 
as many as 2 missed cleavages were allowed.  Assignments were manually verified by 
inspection of the tandem mass spectra and coalesced into Scaffold reports 
(www.proteomesoftware.com). RalA and RalB interacting proteins were identified from 
this initial list by subtractive analysis of the vector transfected cells. Specifically, to 
qualify as a proposed FLAG-Ral interacting partner the protein had to fulfill one of two 
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criteria: the protein had to be identified by at least 2 peptides at greater than 94% 
probability in at least one of two experiments and could not be present in any of the three 
vector-transfected controls; or the protein had to be identified by at least 2 peptides at 
greater than 94% probability in both experiments and could not be present in more than 
one of three vector transfected controls.  
Small interfering RNA (siRNA)  sequences- SiRNA sequences targeting RalA . RalA(5'- 
GACAGGUUUCUGUAGAAGAdTdT-3') and RalB (5'-
GGUGAUCAUGGUUGGCAGCdTdT-3’) were purchased from Dharmacon using 
previously described sequences(8). Pre-designed chemically synthesized siRNA targeting 
RACK1 (Cell Signaling Technology Inc., Danvers, MA) were used according to 
manufacturer’s recommendation. 
Small interfering RNA (siRNA)  transfection procedure- Cells were grown to 50% 
confluence and transfected with Oligofectamine transfection reagent (Invitrogen, 
Carlsbad, CA) according to the manufacturer’s instructions. Briefly, 5 µl of 
Oligofectamine reagent was suspended per 1mL of OPTI-MEM medium (Invitrogen, 
Carlsbad, CA) and allowed to equilibrate at 24-27°C.  A 100 nM final concentration of 
siRNA was suspended and complexed with the liposomes. Cells were briefly washed 
with OPTI-MEM and the transfection mix was plated on top of the cells and incubated at 
37°C. Following an 8 h  incubation, 2mL of complete growth medium, without 
penicillin-streptomycin, was added and the cells were further incubated at 37°C 
overnight. The media was replaced after 24  h with complete growth media for 24 hours. 
Experiments were performed in triplicate.  
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Western blotting—Cells were harvested, and lysed in HEPES lysis buffer as described 
previously (11). Proteins were then resolved by 11.5% SDS-PAGE gel and 
immunoblotted with antibodies against phosphorylated-Ser473 Akt1/2 (9217, Cell 
Signaling Technologies Inc., Danvers, MA), phosphorylated-Thr202/Tyr 204 Erk1/2 
(9101, Cell Signaling Technologies Inc., Danvers, MA), Akt1/2 (N-19, Santa Cruz 
Biotechnology, Santa Cruz, CA), Erk1/2 (p44/p42 MAP Kinase, 9102, Cell Signaling 
Technologies Inc., Danvers, MA), RalA (61022, BD Biosciences Pharmingen, Franklin 
Lakes, NJ), H-Ras (C-20, Santa Cruz Biotechnology, Santa Cruz, CA), K-Ras (F234, 
Santa Cruz Biotechnology, Santa Cruz, CA), RalB (04037, Millipore, Billerika, MA), --
actin (AC15, Sigma-Aldrich, St. Louis, MO) and anti-FLAG M2 monoclonal antibody 
(Sigma-Aldrich, St. Louis, MO). The ECL blotting system (NEN Life Science Products, 
Boston, MA) was used for detection of positive antibody reactions. Experiments were 
performed in triplicate.  
Soft agar clonogenicity assay- For soft agar growth assays, the cell lines were seeded at a 
cell density of 5000/well in triplicate in 12-well culture dishes in 0.3% agar over a 0.6% 
bottom agar layer as previously described(11). Cultures were fed once weekly until 
colonies grew to a suitable size for observation (approximately 14 days). Colonies were 
photographed after overnight incubation with 1 mg/ml MTT in cell growth media. The 
colony number was visually determined and quantified. Experiments were performed in 
triplicate. 
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Results 
 
Use of an ectopically expressed FLAG-tagged Ral-Tandem MS system to isolate and 
identify novel Ral binding partners: Determination of a potential database of Ral 
interacting proteins   
Although RalA and RalB are required for mutant Ras malignant transformation in 
a variety of human cancers, the mechanism by which they mediate Ras transformation is 
not known. This prompted us to identify a database of potential RalA and RalB 
interacting proteins with the ultimate goal of discovering effectors of Ral A and Ral B 
that mediate Ras transformation. To this end we ectopically expressed N-terminal FLAG-
tagged RalA72L and RalB72L in human embryonic kidney cells (HEK-293T) then isolated 
potential Ral-interacting proteins through subsequent FLAG immunoprecipitation, 
separation of protein complexes by SDS-PAGE and protein identification in the various 
gel segments by tandem MS and subsequent SCAFFOLD analysis as described under 
Material and Methods. Figures 17A and 17B show that transient transfection resulted in 
high levels of expression of FLAG-RalA and RalB, respectively, as demonstrated in both 
whole cell lysate as well as FLAG immunoprecipitates as detected by both Ral antibody 
western blots and GelCode Blue stain  
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Figure 17. Expression and immunoprecipitation of FLAG-Ral72L
Figure 17. Expression and immunoprecipitation of FLAG-Ral72L.
Retroviral pBABE plasmids containg either RalA72L (A) or  RalB72L
(B) along with an empty vector sequence were transiently transfected 
into HEK-293T for 48 hours. Cells were collected, lysed, and 
immunoprocipitated following which protein was analyzed for western 
blot analysis or GelCode Blue.
V    RalA
V    RalA
α-FLAG IP 
WCL 
V    RalA
GelCode Blue 
V    RalB
V    RalB
α-FLAG IP 
WCL 
V    RalB
GelCode Blue 
A. B.
α-FLAG IP α-FLAG IP 
Blot:    
FLAG-RalA
FLAG-
RalA
Blot: RalA
Stain: 
GelCodeBlue
RalA
GelCode
Blue
162
Using a proteomic approach we have identified 68 RalA and 28 RalB potential 
interacting proteins. Of these the known Ral-interacting protein Filamin A, as well as the 
closely related Filamin C, were identified as potential RalA and RalB interacting partners 
in this system (see tables 2 and 3, following pages). Additionally, other predicted 
members of known Ral interacting complexes, such as ZO-1 and SC22B, were also 
identified as potential Ral-interacting proteins (see tables 2 and 3, following pages). 
These results provide evidence in support of the overall feasibility of our approach in 
identifying both proposed  direct, as well as indirect, Ral-interacting partners.  
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3GTPB1GTP-binding protein1
67GBLPguanine-nucleotide binding protein
2FLNCfilamin C
5FLNA filamin A
2FEN1flap endonuclease 1 
2FA98B protein FAM98B 
2EF1B elongation factor 1B 
2CT116 uncharacterized protein 
3CSK1casein kinase II subunit-1
4CISY citrate sythase, mitochondrial precursor
3CAPZBF-actin capping protein
2ARP10 actin related protein-10
2AP3M1AP-3 complex subunit-Mu-1
2ACTZalpha-centractin
3ACOT9acyl coenzyme A-thioesterase-9
26PGD 6-phosphogluconate dehydrogenase
31433G 14-3-3 Gamma 
Experiment 2Experiment 1 
Peptides Matched (>94%)
Protein ID Gene name  
RalA SCAFFOLD Results
Table 2. Proposed RalA interacting proteins (pt1)
3VIME vimentin
2VAPB vessicle-associated membrane 
2SPIN3spindlin-3
13SPIN1spindlin-1
2SC22Bvesicle-trafficking protein
3RTN4reticulon-4
27RSSA40S ribosmoal protein SA
62RS640S ribosomal protein S6
3RS2660S ribosmal protein S26
2RS20 40S ribosomal S20
2RS17 40S ribosomal S17
21RS1640S ribosomal S16
2RL7A60S ribosomal L7A
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5PHB prohibitin
4PGK1phosphoglycerate kinase-1
11PA2G4proliferation associated protein-2G4
2NPS3Aprotein NipSnap3
2NELFEnegative elongation factor 
3NELFEnegative elongation factor 
2MPCP phosphate carrier protein
2LUC7L putative RNA-binding protein-7L 
6LRC47 leucine rich repeat protein-47
42KCRU creatine kinase mitochondrial precursor
62KCIEcasein kinase I isoform epsilon
2K2C8keratin  type 2 cytoskeletal-8
7K1C18keratin type 1 cytoskeletal-18
10ILF2interleukin enhancer factor 2
3IF4Heukaryotic translation initiation factor
3IDHPisocitrate dehydrogenase (NADP)
4HNRPG heterogeneous nuclear protein-G
32HNRPF heterogeneous nuclear protein-F
Experiment 2Experiment 1 
Peptides Matched (>94%)
Protein ID Gene name  
RalA SCAFFOLD Results
Table 2. Proposed RalA interacting proteins (pt2)
2RL1760S ribosomal protein-17
5RL10A60S ribosomal protein-10A
3RCN1reticulocalbin-1 
2RANran GTP binding protein  
1410RALAralA
5PUR6multifunctional protein ADE2
2PSMD8 26S proteasome regulatory subunit-8
2PSD1326S proteasome non-ATPase
7PSD1126S proteasome regulatory subunit
2PSA1proteasome subunit alpha 
2PP1B serine-threonine phosphatase-1B 
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22PRDX1peroxiredoxin-1
3PCBP2poly(rC) binding protein-2
3P5CR2pyrroline-5-caraboxylate 
2ODPA pyruvate dehydrogenase E1 
2NUPL2nucleoporin-like 2
4KCRUcreatine kinase
3K1C16keratin, Type I cytoskeletal-16 
12IF32 eukaryotic translation initiation 
22HNRPKheterogeneous nuclear riboprotein
4GTPB1GTP binding protein 
54GBLPguanine-nucleotide binding 
3FLNCfilamin C 
3FLNA filamin A
2ENAHprotein enabled homologue 
6DDX5probable ATP-dependent RNA 
2ARP2actin-like protein 2 
4AHNKneuroblast differentiation factor 
51433E14-3-3 epsilon 
Experiment 2Experiment 1 
Peptides Matched (>94%)
Protein ID Gene name  
RalB SCAFFOLD Results
Table 3. Proposed RalB interacting proteins
6ZO1tight junction protein 
3XAB1XPA-binding protein 
2VIME vimentin
2TBB2Ctubulin beta-2 chain 
3SFRS7splicing factor-S7
72RS640S ribosomal protein-S6
5RS2640S ribosomal protein-S26 
13ROA1heterogeneous nuclear 
2RL1860S ribosomal protein-18
64RALBRalB 
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 RACK1/GBLP interacts with ectopically expressed RalA and RalB in HEK–293T 
cells 
One interesting protein our analysis revealed to be a potential RalA and RalB 
interacting proteins was guanine nucleotide-binding protein GBLP, also known as 
receptor for activated C-kinase1 (RACK1), which is a scaffolding protein able to interact 
simultaneously with several signaling molecules (32).  In order to confirm and validate 
that RalA and RalB interact with RACK1 we ectopically expressed FLAG-tagged 
RalA72L and RalB72L in HEK-293T cells and used FLAG-affinity immunoprecipitation to 
isolate Ral protein complexes. Both RalA72L and RalB72L were expressed at high levels in 
HEK-293T cells (figs. 18A and 18B, following page). In confirmation of our MS/MS 
results both ectopically expressed RalA72L and RalB72L interacted with endogenous 
RACK1 (figs. 18A and 18B). These results demonstrate that a RACK1/Ral complex is 
formed within HEK-293T cells. While these results are strongly suggestive that Ral 
proteins interact with a RACK1 containing complex, if not directly with RACK1, we 
wanted to further validate this interaction using endogenous RalA. 
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Figure 18. RACK1/ GBLP interacts with ectopically expressed Ral72L
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Figure 18. RACK1 interacts with ectopically expressed Ral72L. 
Retroviral pBABE plasmids containg either RalA72L (A) or  RalB72L (B) 
along with an empty vector sequence were transiently transfected into 
HEK-293T for 48 hours. Cells were collected, lysed, and 
immunoprocipitated following which protein was analyzed for western 
blot analysis or GelCode Blue.
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RACK1/GBLP interacts with endogenously expressed RalA in ovarian cancer cells 
We next evaluated whether RACK1 binds RalA in human cancer cells where Ral 
proteins are critical to Ras transformation. We have previously reported (Falsetti and 
Sebti, manuscript in submission) that RalA and RalB expression is required for both H- 
and K-Ras12V transformation of human ovarian surface epithelial cells, which are 
sequentially immortalized by stable expression of human telomerase catalytic subunit 
(hTERT) and simian virus-40 large T-antigen (T80 cells). Therefore, we used T80 cells 
transformed with H-Ras12V (T80H) and K-Ras12V (T80K) to evaluate the binding of 
endogenous RACK1 to endogenous RalA protein and to subsequently determine the 
importance of these interactions to Ras-mediated transformation in this human ovarian 
cancer model.  Figure 3 shows that in  both the non-transformed and Ras-transformed 
T80 isogenic cell lines RalA strongly interacted with endogenous RACK1 but not with 
beta-actin (Figure 19, following page).  Importantly, expression levels of RalA and 
RACK1 did not vary between cell lines. Also, since RalA is GTP-bound in both T80H 
and T80K (Falsetti and Sebti, manuscript in submission) we expected that if RalA 
binding to RACK1 was GTP-dependent there would be increased association in the Ras 
transformed cell lines. However, RalA binding to RACK1 appeared to be GTP-
independent and only varied according to the levels of RalA isolated in each experiment.   
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Figure 19. RACK1/GBLP interacts with endogenous RalA protein
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Figure 19. RACK1 interacts with endogenously expressed RalA. Protein lysate was 
collected from T80, T80H and T80K cells and used for immunoprecipitation of 
endogenous RalA using anti-RalA monoclonal antibody. 
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RACK1 depletion phenocopies the effects of Ral depletion in Ras transformed 
ovarian epithelial cells 
Since we have previously characterized both RalA and RalB expression as being 
required for H- and K- Ras12V-mediated transformation of T80 cells and since RalA and 
RalB were found to interact with RACK1 we endeavored to further define a role for 
RACK1 in Ras-mediated transformation of human epithelial cells. One widely used 
method of determining similar roles for proteins is to determine if the effects of depletion 
of one gene will phenocopy the effects of the other. To that end, we used siRNA to 
specifically and potently deplete T80H and T80K cells of RalA, RalB and RACK1 and 
then examined the effects of single depletion of each gene on Ras transformation. As 
demonstrated in figures 20A and 20B (following page) we were able to specifically and 
potently deplete the cells of RalA, RalB or RACK1 through transient transfection with 
siRNA targeting regions unique to each gene. Furthermore, depletion of RACK1 
phenocopies the effects of Ral depletion on Ras transformation in both T80H and T80K 
cells. Specifically, RalA inhibited T80H clonogenicity in soft agar by 54.9% (p value 
<0.001) and T80K clonogenicity by 51.7% (p value <0.001). Depletion of RalB by 
siRNA inhibited T80H clonogenicity by 53.8% (p value <0.001) and T80K clonogenicity 
by 65.2% (p value <0.001). In support of a role for RACK1 in the Ral-dependent Ras-
mediated transformation of T80 cells RACK1 depletion by siRNA inhibited T80H 
clonogenicity by 59.9% (p value <0.001) and T80K clonogenicity by 34.3% (p value 
<0.01). 
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Figure 20. RACK1/ GBLP depletion phenocopies the effects of Ral 
depletion in Ras-transformed ovarian epithelial cells
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Figure 20 Ras transformation of T80 cells requires expression of RalA/B 
and Akt1/2 but not Raf1. Small interfering RNA (siRNA) specific to RalA, 
RalB, and RACK1 or a negative control siRNA were transfected for 48 hours 
into T80, T80H and T80K cells. Cells were collected, counted using trypan 
blue dye exclusion assay and collected for western blot analysis (A) and an 
equal number of cells were plated for soft agar assay (B) and scored manually 
at the end of two weeks; results are representative of three experiments each 
performed in triplicate.
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Discussion 
 
While Ral proteins are well known to be important components of Ras-mediated 
transformation of multiple human epithelial cell types very little is known about the 
protein-binding partners that govern Ral biological activity. Here, we have used a 
proteomics approach to describe, for the first time, a proposed database of novel Ral-
interacting proteins. Despite a greater than 85% sequence identity RalA and RalB interact 
primarily with different proteins across a wide range of gene ontology sub-groups. 
Furthermore, we have identified and validated RACK1/ GBLP as a novel RalA, and 
RalB, interacting protein. Specifically, we have determined that RACK1 interacts with 
ectopically expressed RalA and RalB as well as with endogenous RalA. Furthermore, 
depletion of RACK1 by siRNA phenocopies the effects of RalA and RalB depletion in 
reducing the ability of multiple Ras isoforms to transform human ovarian epithelial cells.  
These results both dramatically expand the number of proposed Ral protein binding 
partners and identify a specific protein, RACK1, which is at least partially required for 
Ras transformative activity. 
While use of proteomics technology has allowed us to rapidly identify a multitude 
of potential individual protein interactions with both RalA and RalB like all systems 
biology analyses confirmation and validation of these results will require extensive 
efforts to individually characterize each of these potential partners. Nevertheless, we felt 
a further analysis of these potential interacting partners by sorting these proteins using 
SWISS-PROT GO annotation would be helpful in revealing potentially emergent 
biological themes in RalA and RalB biological function.  In particular, these analyses 
revealed cytoskeletal regulation as a potential biological process that could be governed 
173
by both RalA and RalB. Importantly, both RalA and RalB potentially interacted with 
multiple critical regulatory proteins with well-described roles in the regulation of this 
process (9, 13, 24, 40).  Our proteomics analysis suggests that both RalA and RalB 
interact with both Filamin A (FLNA) and Filamin C (FLNC), known regulators of the 
cytoskeleton. Importantly, RalA has been previously shown to interact with Filamin A in 
a GTP-dependent manner (33).  The filamin family consists of three genes: Filamin-A, -
B, and –C; of these Filamin-A is the most well understood. (13). Filamins play a critical 
role in cross-linking the cortical actin cytoskeleton into orthogonal networks and link 
these three dimensional actin structures to the inner leaflet of the cellular membrane (40). 
Furthermore, Filamins modulate the response of cells to their extra-cellular environment 
by regulating changes in shape and motility (38). Interestingly, our analyses revealed 
vimentin (VIME, see tables 2 and 3), an important intermediate filament in mesenchymal 
cells which is commonly overexpressed in cancer cells as part of the epithelial to 
mesenchymal transition (22), to be a potential RalA and RalB interacting protein.  
Another potential RalB associated protein. tubulin beta-2 chain (TBB2C, see table 3), is 
known to form a supramolecular complex with vimentin (9).  Certainly, a further analysis 
of the roles of vimentin and filamin in Ral-driven actin cytoskeletal changes would be 
warranted given these results. 
We validated RACK1 as interacting with both ectopically expressed RalA72L and 
RalB72L  as well as with endogenous RalA in an activation state independent manner. 
Interestingly, there exists a paradigm for small GTPase interaction with RACK1. Rac2, a 
small GTPase highly homologous to RalA and RalB, has been previously shown to 
interact indirectly with RACK1 and this interaction has been shown to regulate natural 
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killer cell adhesion (30). This is particularly interesting given that Ral negatively 
regulates Rac proteins via the Rac-GAP protein RalBP1 (23, 35). Ral and Rac proteins 
regulate similar processes such as cell motility, transformation, invasion, cell-cell 
adhesion and actin reorganization (4, 5, 12, 44). Perhaps, the ability of RalA and RalB to 
subvert Rac processes occurs via both negative regulation of Rac GTP levels and through 
subsequent association with Rac downstream effectors such as RACK1.  
We have also demonstrated, using siRNA, that RACK1 expression was at least 
partially required for both H- and K-Ras12V-mediated transformation of T80 cells and that 
the effects depletion of RACK1 was similar to the effects of RalA or RalB depletion. 
This is consistent with previous work showing that a putative dominant negative isoform 
of GBLP (or RACK1) has been previously shown to reverse K-Ras12V transformation in 
NIH-3T3 cells (2) and to restore  contact inhibition and stress fiber formation (3).  In 
contrast, paradoxically, overexpression of wild-type RACK1 in transformed NIH-3T3 
cells reduces both anchorage-independent and –dependent proliferation (2). Nevertheless, 
other studies support the implication of RACK1 in oncogenesis.  For example, studies 
have used antisense siRNA to inhibit RACK1 expression in NIH-3T3 cells and have 
demonstrated a requirement for RACK1 in cell spreading and cell proliferation (20).  
Furthermore,  RACK1 expression is dramatically increased in both human carcinomas 
and during human ovarian morphogenesis (1).  
In addition to playing apparently contradictory roles in anchorage independent 
proliferation, RACK1 is known to play a role in a variety of cell process such as coupling 
of signal transduction to control of protein transcription and translation (32), recruitment 
of ribosomes to local sites of translation (such as focal adhesions) (32), regulation of cell 
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spreading (3), cytoskeletal organization (20), and cell cycle progression (7). RACK1 
associates with a variety of signal transduction molecules that may account for some of 
these biological activities, such as Protein Kinase C-β (PKC-β), β-integrin and c-Src (29).   
Most interestingly, multiple mechanisms exist through which RACK1 and 
RACK1- interacting proteins, such as PKC isoforms, may regulate Ras. RACK1 has been 
previously shown to associate with p120RasGAP (24), a well-characterized negative 
regulator of Ras activity (31), though the exact significance of the RACK1 interaction in 
RasGAP biological function has not yet been established. RACK1 is a well-characterized 
regulator of multiple PKC isoforms (29), which are known to regulate Ras guanyl 
nucleotide releasing proteins (RasGRPs), positive regulators of Ras signaling (14). PKC 
phosphorylation of K-Ras in the hypervariable C-terminal region results in accumulation 
of K-Ras in the outer mitochondrial membrane and promotes apoptosis (36). 
Additionally, phorbol esters, which activate PKC isoforms, are known to cooperate with 
Ras in transformation and deregulation of diacylglycerol (DAG) has been observed in 
Ras-transformed cells, indicating that Ras and PKC might cooperate during 
transformation (10, 21, 25, 45). Certainly, our results support a role for RACK1 
expression in regulating Ras transformation of human ovarian surface epithelial cells and 
suggest that further study of both the Ral/RACK1 association and the role of RACK1 in 
human ovarian epithelial cell transformation will prove to be interesting avenues of future 
research.  
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In this thesis we have determined novel roles for RalA and RalB in human 
ovarian neoplasia, defined a database of potential Ral interacting proteins, validated 
RACK1 as a novel Ral interacting protein which is required for Ras ovarian 
transformation. Furthermore, in  the second chapter of this thesis we have used an elegant 
experimental chemical biology rescue system to determine the roles of inhibition of RalA 
and RalB prenylation in the GGTI-anti-cancer mechanisms of action. Here we 
determined that both RalA and RalB are validated targets of GGTIs and that inhibition of 
RalA prenylation is required for GGTI-inhibition of anchorage independent growth 
whereas inhibition of RalB prenylation is required for GGTI-mediated suppression of 
proliferation and induction of apoptosis. Rescue of the anti-proliferative and pro-
apoptotic effects of GGTI-2417 by expression of GGTI-resistant RalB also rescued from 
induction of p27kip1, a well known CDK inhibitor of the cell cycle , and suppression of 
survivin, a well known inhibitor of apoptosis.  
 Future work will undoubtedly further define a role for RalB in regulation of the 
survivin gene expression. Data not presented in this thesis certainly indicate the 
importance of RalB in regulating survivin expression. Specifically, we have depleted 
MiaPaCa2 pancreatic cancer cells of survivin by Ral B but not Ral A siRNA. This 
depletion has dramatically reduced the level of survivin expression. Surprisingly, 
depletion of RalB by siRNA does not result in an induction of p27kip1. However, this 
illustrates the complex mechanism of action of GGTIs. GGTIs inhibit phosphorylation of 
Akt in a non-Ral dependent manner. This is relevant in that Ras governs p27kip1 
expression in two synergistic pathways: Akt dependent phosphorylation of the AFX 
transcription factor and Ral dependent phosphorylation of AFX. These two 
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phosphorylation events regulate, respectively, the nuclear import and DNA binding 
activity of AFX, a well characterized regulator of p27kip1 transcription. Further work 
should establish if dual inhibition of Akt and RalB expression is sufficient to induce 
p27kip1 expression and if GGTIs affect AFX phosphorylation and transcriptional activity. 
Certainly, these results suggest new avenues for research in the GGTI anti-tumor 
mechanism of action.  
In Chapter 3 of this thesis, we have both discovered new roles for, and reaffirmed the 
importance of, both RalA and RalB in human cancer. We have defined Ral, as well as 
Akt, as central mediators of Ras-driven ovarian oncogenesis. In contrast to previous 
systems, both RalA and RalB were found to be required for ovarian transformation. 
Surprisingly, Raf1 and Mek1/2 are not required for Ras-transformation in this system. 
Indeed, K-Ras mutants incapable of activating Raf/Mek/Erk signaling were still able fully 
recapitulate the same degree of transformation as fully active oncogenic K-Ras. These 
results suggest that therapeutic intervention in ovarian cancer may be greatly assisted by 
future efforts to target RalGEF/Ral and PI3K/Akt signaling.    
 There remains much work to be done in defining a role for Ral signaling in 
ovarian cancer development. Of particular interest, the lack of a role for Raf-1 signaling 
in this system suggests that the T80 cell system is a more appropriate model for ovarian 
cancer sub-types such as mucinous ovarian and high-grade serous ovarian but not low-
grade serous ovarian. Low-grade serous is characterized by a non-overlapping pattern of 
K-Ras and B-Raf mutation which can be interpreted as clear evidence that these two 
genes operate in a redundant fashion. However, the incidence of K-Ras mutation in high-
grade serous and mucinous coupled with a complete lack of B-Raf mutations and 
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strikingly different disease etiology, as compared to low-grade serous, indicates non-Raf 
oncogenesis may determine the progression of these neoplasms. In order to more fully 
expand on this concept further work will need to determine a role for B-Raf in Ras 
transformation.  Furthermore, further work will need to determine a role for individual 
RalGEFs and PI3K/Akt genes in promoting transformation of T80 cells. If these cells are 
capable of forming tumors in intra-ovarian nude mouse xenograft models, it will be of 
great interest to determine which sub-types of ovarian cancers these cells will most 
closely resemble. Also, assessing patterns of Ral activation and potential mutation of 
RalGEFs in human ovarian tumors, divided by subtype, could serve as further evidence 
of a role for Ral in ovarian cancer.  
 In the fourth chapter of this thesis we have used a subtractive proteomics method 
to determine a database of potential Ral interacting proteins. One of these proteins, 
RACK1, was validated as a Ral interacting protein. The expression of RACK1 was 
required for both H- and K-Ras oncogenesis in T80 cells, a system where RalA and RalB 
are also required. These results indicate a role for RACK1 in Ras-driven ovarian 
oncogenesis and, potentially, in the activity of Ral proteins.  
 Interestingly, RACK1 is a plieotropic scaffolding molecule which interacts with 
other small GTPases, such as Rac1, and serves as a platform for PKC isoforms to interact 
with target substrates. The provocative question then is does RACK1 serve as a platform 
for Ral phosphorylation by PKC? If so what is the role of phosphorylation of Ral? These 
questions are made all the more relevant by the observation that Aurora A phosphorylates 
RalA and that phosphorylation  regulates Ral localization and fuction. Similarly, 
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